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Abstract 
Chronic wounds including pressure, venous, arterial and diabetic neuropathic ulcers, represent a 
significant burden to the healthcare system. These different chronic wound types do not share 
origin or cause; however they have common features as bacterial infection and continuing influx 
of polymorphonuclear neutrophils that release high concentrations of matrix metalloproteases 
(MMPs), myeloperoxidase (MPO) and reactive oxidative species causing excessive degradation 
of the extracellular matrix (ECM) and the growth factors. Because of the multifactorial nature of 
virtually all chronic wounds, the therapeutic wound healing approach should emphasize the 
necessity to investigate wound dressings that possess the ability to directly and indirectly 
modulate the biochemical environment based on the pathology of chronic to encourage the 
healing process. 
The overall aim of the present work was to develop biopolymer wound dressings capable to 
improve the management of chronic wounds. The specific research objective was defined in 
three main targets: i) to balance the proteolytic activity of MMPs, ii) to balance the MPO 
activity and the oxidative environment, and iii) antimicrobial protection. 
 
The first part of the thesis aimed to provide suitable materials to perform bioactive biopolymer-
based wound dressings. The first step was to provide a versatile functionalization of chitosan 
platform to improve the sequestering ability over metal dependent enzymes (MMPs) in chronic 
wounds. In order to impart to chitosan the ability to inhibit MMP, chitosan was functionalized 
with deferent thiol moieties, which can chelate the zinc cation in the active site of the enzyme, 
modifying MMP activity. In addition the combination of -NH2 and -SH chemistry allowed 
grafting of other active agents on the chitosan platform. 
The second step was the identification and evaluation of natural active agents as chronic wound 
healing promoters. Polyphenols from bark, twigs and leaf extracts from the medicinal plant 
Hamamelis virginiana (Witch hazel) were studied for this porpoise and it was found to have 
both a strong antioxidant activity and an inhibitory effect on MPO and collagenase. 
 
The second part of the thesis was focused in the performance and evaluation of new materials 
for wound healing applications. To this aim, chitosan and/or thiolated chitosan were modified 
with H. virginiana extracts following different approaches.  
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The first approach was focused to develop a new method for covalent functionalization of 
thiolated chitosan with polyphenols from H. virginiana extracts. The novelty of this approach 
consists in the use of thiolysis - a common analytical method for proanthocyanidins 
characterization - to covalently functionalize natural macromolecules such as chitosan with 
bioactive phenolic moieties. The phenolics-functionalized chitosan showed improved 
therapeutic properties in vitro.   
The second approach focused on the use of laccase-assisted cross-linking between phenolic 
moieties of H. virginiana with chitosan and gelatin as a functionalization method to obtain 
stable and bioactive hydrogel wound dressings.   H. virginiana extract was oxidized by laccase 
in a one-step process under mild reaction conditions to covalently crosslink chitosan and 
gelatin. The physical and mechanical properties of these hydrogels were investigated using 
different analytical techniques and their potential for chronic wound treatment was evaluated in 
vitro in terms of antibacterial and inhibitory effect on MPO and collagenase. The results 
indicated that the polyphenols exerted a dual role in the hydrogel: i) “passive” – being a 
structural element, and ii) “active” – modifying the chronic wound environment by attenuating 
the deleterious MMPs, MPO and ROS activities, and reducing the bacterial load. 
 
 
 
  
  
KEYWORDS • Chronic wound • Wound dressing • Collagenase • Myeloperoxidase • 
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1.1. Introduction 
Throughout the centuries, mankind has applied a variety of readily available natural substances 
to wounds to staunch bleeding, absorb exudates and promote healing. These include honey, 
cobwebs, leaves and plant extracts, moss and animal dung. In the nineteenth century, primitive 
absorbent dressings were made by unpicking old rope (oakum) or rags in order to obtain a 
fibrous mass of flax or cotton fibres that could be used to pack cavities and soak up exudates or 
blood.  
Simple absorbent dressings played a major role in wound management for many years gradually 
being improved by the addition of low-adherent wound contact layers made from perforated 
plastic films, nonwoven fabrics or other suitable materials.  
Since acute wound healing follows a well-defined pattern resulting in complete wound closure it 
is possible to objectively assess its progression throughout the healing process. On the contrary, 
due to the inherent alterations in the pathophysiology of chronic wounds, the biological effects 
of ageing on the healing process and the direct confounding effect of associated co-morbidities 
in the elderly, the healing of chronic wounds is often protracted, variable and non-uniform [1]. 
Furthermore, in most clinical trials and studies involving wound dressings and devices, 'healing' 
is considered to be the primary predetermined endpoint for both acute and chronic wounds. 
However, products that are aimed to achieve healing in acute wounds may not have the same 
effect in chronic non-healing wounds due to the interaction of various confounding factors such 
as exudate, an unhealthy wound bed and infection.  
Considerable progress has been made on advanced products in the field of wound healing and a 
number of new therapeutic approaches are now available. It is hoped that continued advances 
will come about which, when combined with basic medical and surgical approaches, will 
accelerate the healing of chronic wounds to an extent that is still not possible with current 
therapeutic agents  
The science of wound healing is advancing rapidly, particularly as a result of new therapeutic 
approaches such as growth factors, skin substitutes, and gene and stem cell therapy.  
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1.2. New therapeutic approaches in wound healing 
1.2.1. Gene therapy 
The technology to introduce certain genes into wounds by a variety of physical means or 
biological vectors, including viruses, has existed for some time. These range from ex vivo 
approaches, where cells are manipulated before being re-introduced into the wound, to more 
direct in vivo techniques that may rely on a simple injection or the use of a gene gun [2, 3]. 
Gene therapy as a whole is a very active area of research, with 320 clinical protocols submitted 
to regulatory bodies around the world since 1999 [4].  
 
1.2.2. Stem cell therapy 
Extending the hypothesis that cell therapy may be required to recondition chronic wounds and 
accelerate their healing leads to the conclusion that stem cells may offer even greater advantages 
[5]. 
 
1.2.3. Bioengineered skin. Tissue-engineered 'skin equivalents'  
A number of bioengineered skin products or skin equivalents have become available for the 
treatment of acute and chronic wounds as well as burns [6-8] become as widespread as desired.  
Bioengineered skin may work by delivering living cells which are known as a 'smart material' 
because they are capable of adapting to their environment. There is evidence that some of these 
living constructs are able to release growth factors and cytokines [9, 10] but this cannot yet be 
interpreted as their mechanism of action. It should be noted that some of these allogeneic 
constructs do not survive for more than a few weeks when placed in a chronic wound [11, 12].  
1.2.3.1. Cell-free matrices 
Two approaches are currently used in the production of cell-free dermal matrices. The first is a 
synthetic matrix, usually comprising collagen and other extracellular matrix components, that 
attempts to recreate the desired physical and chemical properties of the dermis. The second 
approach is the use of native dermis, from which the cellular components have been removed. 
This may be treated to preserve the dermal architecture. 
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1.2.3.2. Cell-containing matrices  
As with cell-free matrices, cell-containing matrices include both synthetic matrices, often made 
of polyglycolic acid mesh, as well as natural biological substrates usually comprising collagen 
and glycosaminoglycans. Alternatively, non-cellular matrices, such as the hyaluronic acid 
scaffolds, are recommended for culture with autologous patient cells prior to grafting.  
 
1.2.4. Molecular Therapy 
Therapeutic interventions with the potential to correct degraded ECM. These research finding 
have led to the development of several wound dressings with the aim of inactivating MMPs in 
chronic wounds [13-17] in combination with other therapies. 
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1.3. New medical dressings in wound healing. Factors influencing 
dressing development/selection. 
Many sophisticated dressings are available to the wound care practitioner, made from a wide 
range of materials including polyurethane, salts of alginic acid and other gelable 
polysaccharides such as starch, carboxymethylcellulose and chitosan. These materials may be 
used alone or in combination to form products as diverse as films, foams, fibrous products, 
beads, hydrogels or adhesive gel-forming wafers more commonly called hydrocolloid dressings. 
Depending upon their structure and composition, such dressings may variously be used to 
absorb exudate, combat odour and infection, relieve pain, promote autolytic debridement 
(wound cleansing) or provide and maintain a moist environment at the wound surface to 
facilitate the production of granulation tissue and the process of epithelialisation. 
Some dressings simply absorb exudate or wound fluid and may therefore be suitable for 
application to a variety of different wound types. Others have a very clearly defined specialist 
function and as such have a more limited range of indications. 
This may mean that they are only suitable for the treatment of specific types of wounds or for 
the management of a wider range of wounds during a particular phase of the healing cycle. 
Wound healing is a dynamic process and the performance requirements of a dressing can 
change as the wound progresses towards healing. 
Occasionally, the pain associated with dressing changes can be such that a patient requires 
potent analgesia. In these circumstances the priority may be to identify a product that can be 
easily removed whilst causing minimal pain and trauma [18]. 
If clinical infection is present, it may be necessary to use a dressing that has proven antibacterial 
properties as an adjunct to systemic therapy. 
 
1.3.1. Wound related factors 
1.3.1.1. Wound Type 
A simple wound classification system such as that shown below, forms a useful starting point in 
the selection process. Within this classification wounds are divided into four basic types 
according to their appearance but it will be immediately obvious that these groups could be 
further sub-divided to take account of wound aetiology or depth, for example. 
 
Chapter 1                                                       Wound dressings: State-of-the-art 
1.3. New medical dressings in wound healing. Factors influencing dressing development/selection. 
7 
 
1- Necrotic wounds - covered with devitalised epidermis, frequently black in colour, 
2- Sloughy wounds - which contain a layer of viscous adherent slough, generally yellow in 
colour, 
3- Granulating wounds - which contain significant amounts of highly vascularised granulation 
tissue, generally red or deep pink in colour, 
4- Epithelializing wounds - which show evidence of a pink margin to the wound or isolated pink 
islands on the surface. 
It will be recognised that these descriptions relate not only to different types of wounds but also 
to the various stages through which a single wound may pass as it heals. 
1.3.1.2. Wound Infection 
All wounds, regardless of type, may become colonised by microorganisms which in turn may 
cause the formation of unpleasant odours. If these organisms increase in number past a certain 
critical level, then the wound may develop a clinical infection [19] which may necessitate 
treatment with systemic antibiotics and/or the use of a medicated dressing. Sometimes a wound 
can become infected with an organism that is resistant to normal antimicrobial therapy and in 
these instances a dressing that forms an effective bacterial barrier can be used to cover the 
wound in order to prevent the spread of the resistant organism [20]. 
1.3.1.3. Wound Location 
The location and size of the wound are also important factors. The location of the lesion may 
make application of a particular product almost impossible. 
Wound related factors which have an influence upon dressing development may therefore be 
summarised as shown below. Any or all of these factors may determine the performance 
requirements of a dressing and thus have a marked influence on the development process. 
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Table 1.1. Factors influencing dressing development. 
Wound type 
superficial 
full thickness 
cavity 
Wound description 
necrotic 
sloughy 
granulating 
epithelializing 
Wound 
characteristics 
dry 
moist 
heavily exuding 
malodorous 
excessively painful 
difficult to dress 
liable to bleed easily 
Bacterial profile 
sterile 
colonised 
infected 
infected and potential source of serious cross infection 
 
1.3.2. Product related factors 
The major characteristics of a dressing that determine its suitability for application to a 
particular type of wound include its conformability, fluid and odour absorbing characteristics, 
handling and adhesive properties and the presence of antibacterial and haemostatic activity 
where appropriate. Other more general factors which may also influence product selection 
include the potential for the dressing to cause sensitivity reactions, the ease of application and 
removal (including the production of pain and trauma to wound surface) and the interval 
between dressing changes. Dressings should also not shed particles or fibres that may delay 
healing or predispose the wound to infection. They should also not contain extractables that may 
have an adverse effect of cell growth. 
The product related factors may therefore be summarised as follows; 
• conformability 
• mass or volume (for cavity wounds) 
• fluid handling properties 
• sensitisation potential 
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• odour absorbing properties 
• antibacterial activity 
• haemostatic properties 
• permeability to tissue fluid and microorganisms 
• ease of use 
• pain related factors 
• fibre-fast 
• non-toxic. 
 
1.3.3. Patient related factors 
The major patient related factors may be summarised as follows; 
• wound aetiology, 
• state of continence, 
• known sensitivity to medicated dressings, 
• fragile or easily damaged skin, 
• the need to bathe or shower frequently. 
 
1.3.4. Economic considerations 
The principal economic considerations relate to cost and availability. These factors may 
therefore be summarised as follows; 
 
Table 1.2: Economic factors 
Cost 
unit cost 
treatment cost 
cost of alternative materials 
Availability 
on prescription (Country Sanitary Service ) 
in stores or pharmacy departments 
inclusion in local formularies 
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1.4 Wound dressings in the market 
- Absorbent, perforated plastic film faced dressings 
These dressing were probably the first serious attempt to improve on the cotton gauze 'dry 
dressing', and combine absorbency with reduced risk of adherence. They were also the first to 
be described as 'non-stick' or non adherent. Compared with the fabric dressings used before, 
however, they were certainly low adherent.  
- Absorbent, perforated film dressing with adhesive border 
- Knitted viscose primary dressing BP: These dressings are designed to be used with a 
secondary dressing, depending on the level of absorbency required; they rely on the low 
adherent property of knitted viscose.  
- Povidone iodine fabric dressing: A knitted viscose primary dressing impregnated with 
povidone iodine  
- Vapour permeable adhesive film dressing BP: Though they have found a variety of uses in 
securing primary dressings intravenous cannulae and other medical devices, their main 
indication is lightly exuding, clean, superficial wounds.  
- Activated charcoal cloth with silver 
- Alginate dressings: Possibly one of the most underrated of primary dressings, alginates have 
the supreme advantage over their competitors that the dressing can simply be soaked off with 
saline or a low-force shower; even after several days. Useful for medium to heavily exuding 
wounds (or parts of wounds), alginates are not the dressing of choice for infected wounds; there 
is little point in using alginates for dry wounds.  
- Hydrocolloid dressings: Probably the first dressings to fully exploit the concept of moist 
wound healing; there is still a major role for hydrocolloid dressings in light to medium exuding 
wounds. Hydrocolloids are not ideal for infected wounds. The dressing requires a margin of 
smooth skin around the wound to ensure adhesion. Dressings need frequent change with heavily 
exuding wounds.  
- Hydrogel dressings: Particularly useful for dry, sloughy or necrotic wounds, hydrogels have a 
role in lightly exuding wounds and granulating wounds. Hydrogels are not suitable for infected 
or heavily exuding wounds; an appropriate secondary dressing is required.  
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-Polyurethane foam dressing BP: Indicated for light to medium exuding wounds; not 
recommended for dry superficial wounds. 
- Polyurethane foam/film dressings: Indicated for light to medium exuding wounds; not 
recommended for dry superficial wounds.  
 
Table 1.3. Common wound healing products on market. 
Perforated film absorbent dressings 
 
Absorbent, perforated film with adhesive 
border  
Melolin (Smith & Nephew) 
 
Mepore (Mölnlycke) 
Release (Johnson & Johnson) 
 
Primapore (Smith & Nephew) 
Skintact (Robinson) 
 
 
Knitted viscose primary dressings 
 
Polyurethane foam/film dressing: 
1. with adhesive border 
N-A Dressing (Johnson & Johnson) 
 
Allevyn Adhesive (Smith & Nephew) 
N-A Ultra (Johnson & Johnson)  
 
Lyofoam Extra Adhesive (Seton) 
Tricotex (Smith & Nephew) 
 
Tielle (Adhesive Margin) (Johnson & 
Johnson) 
Vapour permeable adhesive film dressings 
 
Polyurethane foam/film dressing 
 2. Without adhesive border 
Bioclusive (Johnson & Johnson) 
 
Allevyn (Non-adhesive) (Smith & Nephew) 
Cutifilm (Beiersdorf) 
 
Flexipore (Polymedica) 
EpiView (Convatec) 
 
Lyofoam Extra (Non-adhesive) (Seton) 
Mefilm (Mölnlycke) 
 
Spyrosorb (Adhesive) (Perstorp) 
Opsite Flexigrid (Smith & Nephew) 
 
 
Tegaderm (3M Health Care) 
 
 
Povidone iodine fabric dressing  
 
Alginate dressing with absorbent backing  
Inadine (Johnson & Johnson) 
 
Sorbsan Plus (Maersk) 
Hydrocolloid dressings:  
1. Fibrous, No Adhesive Border  
Activated charcoal cloth with silver  
 Aquacel (Convatec) 
 
Actisorb Plus (Johnson & Johnson) 
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Table 1. 3. (continuation) Common wound healing products on market. 
Hydrocolloid dressings: 
2. Semipermeable With Adhesive Border  
Hydrogel dressings 
Comfeel Plus Contour Dressing (Coloplast) 
 
AquaForm (Robert Bailey) 
Granuflex (Bordered) (Convatec) 
 
Granugel Hydrocolloid Gel (Convatec) 
Hydrocoll Border (Hartmann) 
 
Intrasite Gel (Smith & Nephew) 
 Tegasorb Advanced Formulation (3M 
 
Nu-Gel (Johnson and Johnson) 
Health Care) 
 
Purilon Gel (Coloplast) 
  Sterigel (Seton) 
Hydrocolloid dressings: 
3. Semipermeable Without Adhesive Border  
Alginate dressings 
Comfeel (bevelled edge) (Coloplast) 
 
Algisite (Smith & Nephew) 
Comfeel Plus Ulcer Dressing(Coloplast) 
 
Algosteril (Beiersdorf) 
Cutinova Foam (Beiersdorf) 
 
Comfeel SeaSorb (Coloplast) 
Granuflex (Improved Formulation) (Convatec) 
 
Kaltogel (Convatec) 
Hydrocoll Basic(Hartmann) 
 
Kaltostat  (Convatec) 
Tegasorb Advanced Formulation (3M Health 
Care)  
Melgisorb (Molnlycke) 
  Sorbsan (Maersk) 
  Tegagel (3M Health Care) 
Hydrocolloid dressings: 
4. Thin Semipermeable No Adhesive Border  
Hydrocolloid dressings: 
5. Thin Semipermeable + Adhesive Border 
DuoDerm Extra Thin (Convatec) 
 
Combiderm (Convatec) 
Hydrocoll Extra Thin (Hartmann) 
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2.1. Chronic wounds: The health care - an increasing economic problem. 
The EU commission (Brussels, December 5, 2001) has stated that the current demographic 
trends in the EU will lead to a quantitative increase in the demand for health care. As the share 
of population over 65 is to increase from 16.1% in 2000 to 27.5% in 2050, member countries 
are to pursue accessibility, quality and sustainability of the health care system. EU Health policy 
(June, 2004) identified prevention as one of the most effective means to reduce the costs of 
health care. 
Pressure ulcers are a common problem in older patients admitted to hospitals or living in 
nursing homes. They are a serious problem for the older population since they are responsible 
for high morbidity, mortality and impaired quality of life [1-3]. 
 
Table 2.1. Epidemiological Data on Pressure Ulcers, from [4] 
Canada Prevalence of 26% in all healthcare institutions; 25% in acute care, 30% in long-term sub-acute care and 15% in the community 
Germany Prevalence of 5.3–28.3% in hospitals 
Iceland Prevalence of 8.95% 
Italy Prevalence of 8.3% in hospital settings and over 30% in home-care settings 
Japan Prevalence of 5.1% and incidence of 4.4% 
Netherlands Prevalence of 23.1% 
Spain 
Prevalence of 9.1% in home care patients, 8.9% in hospitals and 
10.9% in residential care 
USA Prevalence in hospital of 15%, incidence of 7% 
Europe Overall prevalence of 18.1% with variations between countries 
 
Chronic wounds represent a major health care problem and impose a significant economic 
burden. Studies estimate that more than 2 million people are affected by pressure ulcers and 
another 600,000 to 2.5 million people suffer from leg and foot ulcers of various causes [5]. In 
agreement with epidemiology indicators, pressure ulcers constitute an important problem with a 
high variability in their prevalence (see Table 2.1). The annual total cost for treating chronic 
wounds is in Europe undoubtedly exceeds several thousand million Euros.  
Currently, there is not one accepted treatment for this costly medical crisis, which causes a vast 
amount of amputations and significantly compromises the patient’s quality of life. 
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Complications from pressure ulcers are estimated to result in the deaths of 7% to 8% of persons 
with spinal cord injury. Thus, good nursing skills, including regular washing and debridement, 
application of antimicrobials to prevent the infection, and daily changing the dressing, can play 
a major role in improving the patient’s outcome. However, in many cases, the aforementioned 
procedures are simply not enough to promote wound closure. Intrinsic health factors, such as 
diabetes, immune status and, in many cases, age are often the major inhibitory factors to wound 
healing [6] 
The magnitude of this problem can be expected to increase as our population ages. This will 
place a further burden on the health care system. In times of cost pressure, as nowadays, it is 
very easy to think that money can be saved by reducing staff training, avoiding the need to buy 
relatively expensive preventative equipment or buying the cheapest products, but when focusing 
on pressure ulcers it is clear that the consequences of such short-sightedness are higher costs in 
the long term, inefficient use of healthcare services, frustration in many healthcare 
professionals, unnecessary pain and discomfort for patients and even avoidable mortality and an 
increase in litigation against healthcare professionals and institutions [4]. 
As it is outlined in the state-of-the-art section, wound dressings currently on the market do not 
fully address all of the physiological issues associated with chronic wounds. Many sophisticated 
dressings are available for the wound care treatment, made from a wide range of materials 
including polyurethane, salts of alginic acid and other gelable polysaccharides such as starch 
and carboxymethylcellulose. These materials may be used alone or in combination to form 
products as diverse as films, foams, fibrous products, beads, hydrogels or adhesive gel-forming 
wafers more commonly called hydrocolloid dressings.  
Depending upon their structure and composition, such dressings may variously be used to 
absorb exudates, combat odor and infection, relieve pain, promote autolytic debridement 
(wound cleansing) or provide and maintain a moist environment at the wound surface to 
facilitate the production of granulation tissue and the process of epithelization. 
Some dressings simply absorb exudates or wound fluid and may therefore be suitable for 
application to a variety of different wound types. Others have a very clearly defined specialist 
function and as such have a more limited range of indications. This may mean that they are only 
suitable for the treatment of specific types of wounds or for the management of a wider range of 
wounds during a particular phase of the healing cycle. 
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In 2009 the advanced wound management market was estimated at $5.0 billion, with a grow 
rate of 4% over the preceding year [7]. It is a huge market and companies are willing to invest 
large amounts of money into this type of product development. In the state-of-the-art section 
(table 1.3.), it is showed the main part of released products on the chronic wound management 
market. 
The aging population, along with the increased prevalence of Type II diabetes, has led many to 
concentrate on improving wound dressing treatments for chronic wounds. The development of 
innovative multifunctional textiles will lead to radical breakthroughs in prevention and 
treatment of chronic diseases and thereby realizing important savings and improved quality of 
life. However, as this is an incredibly complex issue, many factors need to be taken into 
account. With this in mind, this literature review will provide background information on 
wound healing; thus will summarize the characteristics of chronic ulcers, including the role of 
protease activity, myeloperoxidase activity, reactive oxygen species and bacterial infection; and 
will also focus on functionalization and modification of biopolymeric materials.
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2.2. Acute wounds and chronic wounds 
From the clinical point of view wounds are generally classified into acute and chronic wounds. 
Acute wounds, either traumatic or surgical follow the healing process at a predictable rate 
whereas the non-healing wounds will not progress in a predictable manner but become chronic. 
When the skin becomes compromised, the normal wound healing process resolves the injury. 
Understanding wound healing process will provide knowledge for evaluating the stage at which 
healing stops, the factors that may have contributed to the disturbing wound healing process and 
why could end up being a chronic wound. 
 
2.2.1. Normal wound healing 
 
 
 
Figure 2. 1. Physiological stages of wound repair and sequence of events during normal wound healing.  
 
The wound healing process is a highly ordered and extremely complex process between orderly 
expressed cell types, extracellular matrix and an array of soluble mediators, designed to restore 
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skin integrity. This process involves keratinocyte and fibroblast proliferation, regeneration of 
the extracellular matrix, connective tissue regeneration, and blood vessel growth. 
The classic model of wound healing has been traditionally divided into three or four stages 
(hemostasis is not considered a phase by some authors): inflammation, cellular proliferation 
and tissue remodeling and maturation. Although these three stages sequentially follow each 
other, they are not mutually exclusive and they are overlapped phases by which the body repairs 
the damaged tissue or organ (see fig 2.1). 
When an injury to the skin occurs, the development of inflammatory response by the body 
immune system is the first step, necessary to debride the wound of foreign material and 
damaged tissue and to control bioburden. A number of cells of the immune system are involved 
and these include platelets that form a blood clot, the white blood cells that engulf the 
microorganisms, as well as the mesenchymal cells that develop into fibroblasts. A 
reconstructive phase characterized by the deposition of granulation tissue, re-epithelialization 
and wound contraction, and finally the remodeling phase and scar formation [8]. 
Recently, a complementary model has been described [9]. In this construct, the process of 
wound healing is divided into two major phases: early phase and cellular phase: 
The early phase, which begins immediately following skin injury, involves cascading molecular 
and cellular events leading to hemostasis and formation of an early, makeshift extracellular 
matrix—providing structural support for cellular attachment and subsequent cellular 
proliferation. 
The cellular phase follows the early phase, and involves several types of cells working together 
to mount an inflammatory response, synthesize granulation tissue, and restore the epithelial 
layer. Nevertheless, the following text is based on the classic model of wound healing.  
2.2.1.1. The inflammatory phase  
The inflammatory phase begins immediately after injury can be divided into bleeding, 
hemostasis and inflammation [10]. It involves predominantly white blood cells such as 
neutrophils, monocytes, and macrophages. These cells mount an initial defense against 
microbial invasion and secrete a variety of proteolytic enzymes capable of liquefying nonviable 
tissue components and microorganisms in the wound area. 
The bleeding from a fresh wound has the effect of cleansing the wound of some of the invading 
foreign bodies debris. Within seconds, vasoconstriction, platelet adhesion and aggregation, 
along with blood coagulation, result the formation of thrombus which encourages hemostasis. 
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The hemostasis begins immediately after wounding, just before the inflammatory phase is 
initiated, with vascular constriction and fibrin clot formation. The clot provides a scaffold for 
the migrating cells such as neutrophils, monocytes, fibroblasts, and endothelial cells. The clot 
and surrounding wound tissue release pro-inflammatory cytokines and growth factors.  Once  
bleeding  is  controlled,  inflammatory  cells  migrate  into  the wound  (chemotaxis)  and  
promote  the  inflammatory  phase, which  is  characterized  by  the  sequential  infiltration  of  
neutrophils,  macrophages,  and  lymphocytes [11-13]. A  critical function  of  neutrophils  is  
the  clearance  of  invading  microbes and cellular debris in the wound area, although these cells 
also release proteases such as  Matrix metalloproteinases (MMPs) and serine proteases which 
can cleave extracellular matrix components in the wound area, and reactive oxygen species 
(ROS), which cause some additional bystander damage. Thereafter, the tissue and blood 
monocytes are transformed into macrophages [12]. Macrophages are responsible for inducing 
and clearing apoptotic cells (including neutrophils), leading to the resolution of inflammation. 
As  macrophages  clear  these apoptotic cells, they undergo a phenotypic transition to a  
reparative  state  that  stimulates  keratinocytes,  fibroblasts,  and  angiogenesis  to  promote  
tissue  regeneration  [14, 15]. In this way, macrophages promote the transition to the 
proliferative phase of healing. 
2.2.1.2. Proliferative phase 
The proliferative phase generally follows and overlaps with the inflammatory phase, and is 
characterized by angiogenesis, collagen deposition, granulation tissue formation and re-
epithelialization [16]. In angiogenesis, new blood vessels are formed by vascular endothelial 
cells [17]. In fibroplasia and granulation tissue formation, fibroblasts grow and form a new, 
provisional extracellular matrix (ECM) by excreting collagen, fibronectin as  well  as  
glycosaminoglycans  and  proteoglycans,  which  are  major  components  of  the ECM [16]. 
While angiogenesis, fibroplasia and granulation tissue formation is taking place in deep tissue, 
re-epithelialization through migration of epidermal cells helps restore epithelial integrity is 
taking place on the wound surface, providing cover for the new tissue.  
The process of angiogenesis, also called neovascularization occurs concurrently with fibroblast 
proliferation when endothelial cells migrate to the area of the wound, promoting the growth of 
capillaries into the area of injury. These are essential to bring oxygen and nutrients to the 
fibroblasts and other cells that are involved in the reconstruction process. Thus angiogenesis is 
imperative for other stages in wound healing. It is stimulated by macrophages, responding to 
low oxygen levels in the damaged area. Stem cells of endothelial cells, originating from parts of 
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uninjured blood vessels, develop pseudopodia and push through the ECM into the wound site to 
establish new blood vessels [18]. Endothelial cells are attracted to the wound area by fibronectin 
found on the fibrin scab and chemotactically by angiogenic factors released by other cells [19, 
20] e.g. from macrophages and platelets when in a low-oxygen environment. Endothelial 
growth and proliferation are also directly stimulated by hypoxia, and presence of lactic acid in 
the wound [21]. 
To migrate, endothelial cells require the local secretion of proteolytic enzymes, especially 
MMPs to degrade the clot and part of the ECM [22]. MMPs digest basement membrane and 
ECM to allow cell migration, proliferation and angiogenesis [22]. When macrophages and other 
growth factor-producing cells are no longer in a hypoxic, lactic acid-filled environment, they 
stop producing angiogenic factors [21]. Thus, when tissue is adequately perfused, migration and 
proliferation of endothelial cells are reduced. When the capillary system is sufficiently repaired 
and tissue oxygenation and metabolic needs are met, eventually blood vessels that are no longer 
needed die by apoptosis[23] 
Fibroblasts appear shortly after the inflammatory stage, attracted to the area by platelet-derived 
growth factor, fibroblast growth factor and other mediators. They migrate into the wound area 
from surrounding tissues and quickly become the predominant cells [24]. After the fibroblasts 
have migrated into the provisional wound matrix they proliferate and begin to synthesize non-
cellular support of ECM structure that includes collagen, elastin, glycoproteins, fibronectin and 
hyaluronan [20, 25]. This process of fibroblast proliferation and synthetic activity is known as 
fibroplasia. The new capillaries embedded in a loosely ECM that give granulation tissue its 
characteristic uneven or granular appearance. – hence called granular tissue. 
Granulation tissue consists of new blood vessels, fibroblasts, inflammatory cells, endothelial 
cells, myofibroblasts, and the components of a new, provisional extracellular matrix (ECM). 
The provisional ECM is different in composition from the ECM in normal tissue and its 
components originate from fibroblasts. One of fibroblasts’ most important duty is the 
production of collagen. Collagen deposition is important because it increases the strength of the 
wound. Before it is laid down, the only thing holding the wound closed is the fibrin-fibronectin 
clot, which does not provide much resistance to traumatic injury. Also, cells involved in 
inflammation, angiogenesis, and connective tissue construction attach to, grow and differentiate 
on the collagen matrix laid down by fibroblasts [26].  
The formation of granulation tissue in an open wound allows the re-epithelialization phase to 
take place as epithelial cells migrate across the new tissue to form a barrier between the wound 
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and the environment. During the re-epithelialization, the provisional wound matrix is 
remodeled and replaced with scar tissue, consisting of new collagen fibers, proteoglycans and 
elastin fibers, which partially restore the structure and function of the tissue. This is 
accomplished by the migration, proliferation and differentiation of epithelial cells, dermal 
fibroblasts and vascular endothelial cells from adjacent uninjured tissue and stem cells that 
originate in the bone marrow and circulate to the wound site [26]. 
Fibroblasts in the normal dermis are typically quiescent and sparsely distributed, in contrast to 
those in the provisional wound matrix and granulation tissue, which are numerous and active. 
Fibroblasts migrate into the wound in response to soluble cytokines and growth factors, which 
are initially released from platelets when they degranulate and later by macrophages in the 
wound [26].  
The direction of fibroblast movement is determined by the concentration gradient of 
chemotactic factors and by the alignment of the fibrils in the ECM and provisional matrix. 
Fibroblasts tend to migrate along these fibrils, as opposed to across them. They begin moving 
by binding first to matrix components such as collagen, fibronectin, vitronectin and fibrin via 
their cell-surface integrin receptors [27]. While one end of the fibroblast remains bound to the 
matrix component, the cell extends a cytoplasmic projection to find another binding site. When 
the next site is found, the attachment to the original site is broken by MMPs secreted by the 
fibroblast, essential for the migration of cells through the ECM. The cell uses its cytoskeletal 
network of actin fibers to pull itself forward. Partially degraded collagen molecules will not 
bind (interact) properly with new collagen molecules synthesized during scar formation, 
resulting in disorganized, weak ECM, so the degraded collagen molecules must be removed by 
controlled action of the MMPs. This process must be carefully controlled by tissue inhibitors of 
MMPs (TIMPs) to prevent the MMPs from degrading intact, functional matrix [28]. 
2.2.1.3. Remodeling phase 
Following robust proliferation and ECM synthesis, wound healing enters the final remodeling 
phase, which can last for years. In the remodeling phase the wound matures. One critical feature 
of the remodeling phase is ECM remodeling to an architecture that approaches that of the 
normal tissue. The wound also undergoes physical contraction throughout the entire wound-
healing  process,  which  is  believed  to  be  mediated  by  contractile fibroblasts 
(myofibroblasts) that appear in the wound [11, 13, 29]  
Collagen is remodeled and realigned along tension lines where the wound is contracting. During 
this process the cells that are no longer needed are removed by apoptosis. When the levels of 
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collagen production and degradation equalize, the maturation phase of tissue repair is said to 
have begun [21]. During Maturation, type III collagen, which is prevalent during proliferation, 
is gradually degraded and the stronger type I collagen is laid down in its place [30]. Originally 
disorganized collagen fibers are rearranged, cross-linked, and aligned along tension lines [21]. 
Then, the phase progresses, tensile strength of the wound increases. The strength approaches 
50% that of normal tissue by three months after injury and ultimately becomes as much as 80% 
as strong as normal tissue [31]. Since activity at the wound site is reduced, the scar loses its 
erythematous appearance as blood cells that are no longer needed are removed by apoptosis [21] 
 
2.2.2. Chronic wounds 
When the healing process is interrupted, a chronic wound is produced. Chronic wounds have 
been defined as wounds that have failed to return to functional and anatomical integrity in a 
timely fashion, or wounds that have proceeded through the repair process without a normal 
functional end result. All  chronic wounds  begin as  acute wounds and the  process  of  wound  
healing  described  above  may  be  hindered  and  even  stopped  as  a result of various factors.  
Such  factors  include  age  which  has  a  major  impact  on  healing because  of  decrease  in  
inflammatory  response  and  physiological  processes  such  as blood  circulation,  reduction  in  
collagen  formation,  basement  membrane  degeneration [32]. Malnutrition prevents wound 
healing by decreasing collagen production and other proteins needed for wound repair. Bacteria 
in high concentrations produce toxic end products and compete with cells in the granulation 
tissue for available nutrients  in  the  wound  bed  [33]. Stress has also been implicated in the 
impaired healing process.  Studies  have  shown  that  decreased  wound  healing  is associated 
with psychological stressors such as pain and noise [34]. Although any wound can become 
chronic, most chronic wounds are diabetic foot ulcer, venous leg ulcers and pressure ulcer. 
Although these wounds all have very different etiologies, chronic wound development 
invariably stems from three factors; the cellular and systemic effects of aging, repeated 
ischemia–reperfusion injury, and bacterial contamination resulting in an inflammatory 
response [35].  These factors promote a decreased growth factors, decreased keratinocyte 
migration, increased reactive oxygen species (ROS), increased tissue proteases, and microbial 
contamination.
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2.3. Pressure ulcers 
Pressure ulcer is the most widely used and preferred term for a wound that develops as a result 
of pressure on a bony prominence that leads to soft tissue damage. Other terms that have been 
used to describe such wounds are decubitus ulcer, pressure sore, or bedsores. A pressure ulcer is 
classified as a type of chronic wound due to the time of injury is often unknown, and healing is 
prolonged and disorganized. 
Pressure ulcers occur as result of external forces, pressure, shear, and friction, in combination 
with patient risk factors that influence tissue tolerance and promote ulcer development. These 3 
forces combine to result in an ischemia (inadequate blood supply to an area of skin). Following 
a localized ischemic injury, a cascade of physiological events occurs characterized by anaerobic 
metabolism, production of toxic metabolites, acidosis, increased cell membrane permeability, 
cellular edema, cell death, and finally tissue necrosis. Paradoxically, reperfusion of ischemic 
tissues introduces an influx of inflammatory mediators and free radicals that can initially 
promote further tissue damage rather than restore normal function [36, 37].  The cellular injury 
is known as ischemia-reperfusion injury. This injury promotes the occlusion of blood vessels. 
Swelling of capillary endothelial cells, plugging of capillaries by leucocytes, fibrin deposits and 
microthrombi, contributes to the failure of capillary perfusion after prolonged ischemia [38].  
Once perfusion decreases, tissue hypoxia occurs, which results in skin necrosis and pressure 
ulcer formation. Sustained pressure over a bony prominence for 1 to 2 hours can cause tissue 
damage, and pressure ulcers may develop within 2 to 6 hours. Although injury is often incurred 
by excessive mechanical loads, studies have indicated that exposure of low pressure over a 
protracted duration may have the same detrimental effect. Common locations for pressure ulcer 
formation include the sacrum, trochanter, heels, and elbows [39], as is depicted in figure 2.2. 
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Figure 2.2. Causes of pressure sore: For short periods, the skin can survive exposure even to heavy 
pressure without being damaged. If the pressure persists, however, the affected skin cells become 
completely ischemic because of the increasing impairment of blood circulation and the skin cells die. 
Diagram showing the areas of the body at risk of pressure sores when lying down (from Cancer Help UK, 
original diagram by the Tissue Viability Society) 
 
2.3.1. Classification and degrees of severity of decubitus 
Considering the origins of pressure ulcer, it is clear why the ulceration develops in stages: The 
longer the area of skin is exposed to pressure, the more severe the tissue damage becomes. 
The classification of degrees of severity is therefore based on an evaluation of which layers of 
skin have already been destroyed by the pressure damage. Various decubitus classifications are 
used, such as Daniel’s classification into five degrees of severity, which is used particularly in 
the surgical field, or the most commonly used classification into four degrees of severity 
developed by the “National Pressure Ulcer Advisory Panel” in 1989. 
-Stage I: An observable, pressure-related alteration of intact skin, whose indicators as compared 
to an adjacent or opposite area on the body may include changes in one or more of the following 
parameters: hyperthermia of the skin (warmth or coolness), induration or edema, tissue 
consistency (firm or boggy feeling), sensation (pain, itching), and depigmentation. 
With consistent pressure relief the reddening pales after several hours or days, depending on the 
severity of the prior impairment of blood perfusion. 
Pressure 
- Local impairment of blood flow 
- Oxygen deficiency / increase in 
toxic metabolism products 
- Increase in capillarity permeability 
vascular dilation, cellular infiltration, 
edema formation 
- Blister formation 
- Complete ischemia, irreversible 
death of skin cells 
Ulcer/Necrosis 
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-Stage II: Partial loss of epidermis as far as the dermis. This is a superficial ulcer which may 
manifest clinically as an abrasion, blister or shallow crater. 
-Stage III: Damage to all layers of skin (epidermis, dermis and subcutis), which may extend as 
far as the fascia beneath the skin, although the fascia is not yet affected. Clinically, the pressure 
ulcer looks like an open sore with or without undermining of the surrounding tissue. 
-Stage IV: Loss of skin involving the entire skin thickness with extensive tissue necrosis and 
damage to muscles, tendons and bones. Undermining and pocket formation are also commonly 
seen. 
 
 
 
Figure 2.3. Classification of the severity of pressure ulcer is based on which tissue layers have already 
been destroyed by exposure to pressure. From PAUL HARTMANN AG Phase-specific wound 
management of decubitus ulcer April 2006 ISBN 3-929870-44-4 
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2.4. A molecular and biochemical view of chronic wounds /pressure ulcers 
2.4.1. Chronic wound environment and impaired healing 
Proteolytic degradation of extra-cellular matrix (ECM) proteins is an essential feature of repair 
and remodeling during cutaneous wound healing. Degradation of ECM by proteinases plays a 
substantial role in tissue remodeling during normal wound healing. In acute wound a balance 
between proteinase inhibitors and proteinases activity (e.g. MMPs) regulates the degradation 
and regeneration of the ECM. Repeated ischemia perfusion events potentiate the cycle of 
inflammatory cytokines, leukocyte migration, and protease and oxidant injury with loss of tissue 
perfusion. Thus, after ischemia perfusion injury, these proteolytic events become excessive and 
are not adequately controlled; this proteolytic imbalance may lead to generalized tissue 
destruction. Such massive destruction of the ECM is a key factor in the impairment of healing 
as seen in chronic ulcers [40, 41]. A number of these changes may be further enhanced by 
environmental factors, such as bacteria and their metabolites [42] and the generation of reactive 
oxygen species (ROS), within the wound [43, 44] 
The over-abundant neutrophil infiltration is responsible for the chronic inflammation 
characteristic of non-healing pressure ulcers. The neutrophils release significant amounts of 
oxidative enzymes such as myeloperoxidase (MPO) and proteolytic enzymes such as 
collagenase (MMP-8) that is responsible for destruction of the connective tissue matrix [45, 46]. 
In addition, the neutrophils release an enzyme called elastase that is capable of destroying 
important healing grow factors [47]. Another marker of these chronic ulcers is an environment 
containing excessive reactive oxygen species (ROS) that further damage the cells and healing 
tissues [48]. These chronic ulcers will not heal until the chronic inflammation is reduced. 
Furthermore, all chronic wounds intrinsically contain bacteria, and the process of wound 
healing can still occur in their presence. Therefore, it is not the presence of bacteria [49] but 
their interaction with the host that determines the organisms’ influence on chronic wound 
healing. The accumulation of necrotic tissue or slough in a chronic wound promotes bacterial 
colonization and bacterial components may contribute to impaired repair mechanisms of the 
host by interference with cell–matrix interactions or attenuating the inflammatory response [50]. 
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Figure 2.4. Features of chronic wounds. The pathophysiology of chronic wounds is thought to be based on 
a prolonged inflammatory phase and the destructive processes dominate. Adapted from [51]. 
 
2.4.2. The ischemia-reperfusion injury and role of reactive oxygen species 
The ischemia-reperfusion injury leads to a decrease in oxygen tension in the cells results in the 
activation of control mechanisms to maintain steady state. With the restoration of the blood 
supply and reintroduction of oxygen, toxic oxygen derived free radicals may be formed. Under 
normal circumstances oxygen-derived free radicals are buffered by free-radical scavenging 
mechanisms. However, when there is an overproduction of reactive oxygen species (ROS), or a 
decrease of scavengers as in oxidative stress, free radicals can initiate a sequence of biochemical 
and cellular events, causing extensive damage to the surrounding tissues [52]. The failure to 
reperfuse, the so-called, no-reflow phenomenon, is also a result of overproduction of free 
radicals [53, 54].  An important source of free radicals is derived from the neutrophilic 
leucocytes. While they fight pathogens, neutrophils also release inflammatory cytokines and 
enzymes that damage cells [35, 55]. One of their important jobs is to produce ROS to kill 
bacteria, for which they use an enzyme called myeloperoxidase (MPO) [35]. The enzymes and 
ROS produced by neutrophils and other leukocytes damage cells and prevent cell proliferation 
and wound closure by damaging DNA, lipids, proteins[56], the extracellular matrix (ECM), and 
cytokines impairing the wound healing [35]. 
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2.4.3. Alterations in protease activity, the role of MMP’s  
Alteration of the ECM is integral to the resolution of wound healing but also has implications in 
regulation of inflammation. MMPs are key regulators of multiple aspects of tissue repair and the 
study of these enzymes will provide insight into possible therapies. 
 
Figure 2.5.  Protease levels in normal and chronic wounds 
 
1.4.3.1. MMPs and their role in the normal wound healing process 
The MMPs are zinc-dependent endopeptidases collectively capable of degrading essentially all 
components of ECM [57]. Controlled breakdown of ECM by MMPs plays an important role in 
detachment and migration of cells, as well as in tissue remodeling in several physiological 
situations, e.g. developmental tissue morphogenesis, tissue repair, and angiogenesis. It is likely 
that in these situations distinct MMPs cooperate in parallel and/or cascade- like fashion to 
achieve effective and targeted ECM degradation, which is also controlled by specific tissue 
inhibitors of metalloproteinases (TIMPs). In skin, several different types of cells are capable of 
producing MMPs: keratinocytes, fibroblasts, macrophages, endothelial cells, mast cells, 
eosinophils, and neutrophils. 
MMPs play essential and beneficial roles in normal wound healing processes. MMP enzyme 
family may theoretically be involved in various tasks during wound repair summarized in table 
2.2. 
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Table 2.2. Main roles of MMPs in normal wound healing. Adapted from [58] 
Main phase of healing Role of MMPs 
Inflammation Removal of damaged ECM (aids autolytic debridement) 
Proliferation 
Degradation of capillary basement membrane for angiogenesis 
Aiding detachment and migration of cells 
Remodeling 
Contraction of scar ECM 
Remodeling of scar ECM 
Wound healing Regulation of activities of certain growth factors [59] 
 
Removal of damaged ECM [58] 
MMPs break down the damaged ECM that occurs at the edge of acute skin wounds. This 
enables new ECM components (e.g. collagen, fibronectin, and proteoglycans) synthesized by 
wound cells to integrate correctly with intact ECM components at the wound edges. 
In addition, MMPs help to slough out bacterial biofilms. The MMPs secreted by inflammatory 
cells surrounding biofilms digest (loosen) the attachments between the bacterial biofilms and 
the wound bed. 
Angiogenesis 
MMPs degrade the basement membrane that surrounds capillaries. This allows vascular 
endothelial cells to migrate from capillaries near the wound and to establish new blood vessels 
into the wound bed [60, 61] 
Migration of cells 
MMPs (especially MMP-1) are required for migration of epithelial cells, fibroblasts, and 
vascular endothelial cells across or through the ECM. When epithelial cells at the edge of a 
wound begin to proliferate and migrate as a sheet across the wound bed, the epithelial cells just 
trailing behind the leading edge of the sheet secrete MMP-1. This partially digests the type 1 
collagen and weakens the attachment of the cells' membranes to the matrix, allowing the cells to 
move across the collagen matrix [61, 62]  
Contraction 
MMPs secreted by myofibroblasts are necessary for contraction of newly synthesized scar 
ECM. Large excision wounds in humans can contract up to about 20% of the initial wound area 
[63, 64]   
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Scar remodeling 
Repair of skin wounds initially produces a highly disorganized scar matrix. However, wound 
cells continue to produce low levels of MMPs long after the initial scar is formed. These MMPs 
slowly remove the disorganized ECM, which is gradually replaced by ECM with a more normal 
and more highly organized structure [65, 66]  
2.4.3.2. MMPs in chronic wound 
However, when the level of protease activity is too high the delicate balance between tissue 
breakdown and repair is disturbed. This unbalanced proteolytic activity, mainly due to excessive 
MMPs, is the key factor responsible of the persistent inflammatory response at the wound site, 
which impairs local tissue protective mechanisms leading to a non-healing wound. [67-69]  It is 
currently accepted that in addition to their involvement in protein breakdown of the extracellular 
network, excessive metalloproteinases also break down growth factors [41, 47]. 
After reperfusion, in response to pro-inflammatory cytokines, the activated leukocytes 
(neutrophils and macrophages) adhere to the endothelial cell, release protease enzymes causing 
inflammation with significant cellular and tissue injury [70].  
Pro-inflammatory cytokines are considered as potent inducers of MMP expression in chronic 
wounds, and they have been shown to down regulate the expression of tissue inhibitor of 
metalloproteinases (TIMPs), thus creating an environment with a relative excess of MMP 
activity. Pressure ulcers are characterized by significantly higher levels of MMP-1 and MMP-8 
and lower levels of TIMP-1 than normal wounds. Interestingly, in normal healing wounds, 
collagenases are present almost exclusively in their inactive forms, whereas nonhealing ulcers 
possess significant levels of the active enzymes [40, 46]. In addition, elevated levels of various 
serine proteinases have been found at the chronic wound site, particularly of neutrophil origin. 
These include particularly neutrophil elastase [25, 69] 
Indeed, the major protease inhibitors, as well as components of the provisional wound matrix, 
have been shown to be degraded and inactivated within the chronic wound environment [25]. 
Growth factors pivotal for repair are targets of wound proteases, and they are inactivated by 
proteolytic cleavage [23, 71]. In summary, the involvement of excessive MMPs in wounds 
contributes to the development of delayed healing, via three mechanisms: 
• Protein breakdown of components of the neo-matrix, 
• Breakdown of growth factors, 
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• Breakdown of TIMP proteins, thereby blocking any feedback mechanism linked to 
proteinase hyperactivity. 
Consequently, one of the current treatment strategies in the management of chronic wounds is 
directly aimed at restoring the proteolytic unbalance of MMPs. However, since MMP activity is 
necessary for normal wound healing, to ascertain the potential of MMP inhibitors as 
therapeutics, it is crucial to understand MMPs mode of action. 
2.4.3.3. MMP, chemical structure and mode of action  
MMPs have since been identified as the major enzymes responsible for turnover of extracellular 
matrix by proteolytic degradation of virtually all proteinaceous components of the ECM [57]. 
At present, the MMPs consist of 23 distinct proteases in humans (see table 2.3.), which can be 
divided into subgroups of collagenases, gelatinases, stromelysins, and membrane type MMPs 
(MT-MMPs) according to their substrate specificity and primary structure (see figure 2.6.).  
 
 
 
Figure 2.6. Domain structure of secreted and membrane-bound Matrix metalloproteinases. MMPs are 
comprised of different subdomains and have the “minimal domain” in common, which contains three 
principal regions: an aminoterminal signal sequence (Pre) to be cleaved by the signal peptidase during 
entry into the endoplasmic reticulum, a pro-domain (Pro) containing a thiol-group (-SH) and a furin 
cleavage site, and the catalytic domain with a zinc-binding site (Zn2+) [72]. 
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Table 2.3. Overview of the identified MMPs and their common names. From [73]  
MMP Alternative name MMP Alternative name 
1 
Collagenase-1 
16 Membrane type-3 MMP 
Interstitial collagenase 
2 
Gelatinase A 
17 Membrane type-4 MMP 
72-kDa type IV collagenase 
3 
Stromelysin-1 
18 Human ortholog of Xenopus MMP-18 
Transin-1 
7 
Matrilysin 
19 RASI-1, occasionally referred to as stromelysin-4 Pump-1 
8 
Collagenase-2 
20 Enamelysin 
Neutrophil collagenase 
9 
Gelatinase B 
21 
X-MMP 
92-kDa type IV collagenase Human ortholog of Xenopus xMMP 
10 Stromelysin-2 23 
Cysteine array MMP 
Femalysin 
MMP-22 
11 Stromelysin-3 24 Membrane type-5 MMP 
12 Macrophage metallo-elastase 25 
Membrane type-6 MMP 
Leukolysin 
13 Collagenase-3 26 Matrilysin-2/endometase 
14 Membrane type-1 MMP 27 C-MMP 
15 Membrane type-2 MMP 28 Epilysin 
 
The majority of zinc-dependent metallopeptidases (with the notable exception of the 
carboxypeptidases) share a common pattern of primary structure in the part of their sequence 
involved in the binding of zinc, and can be grouped together as a superfamily, known as the 
metzincins, on the basis of this sequence similarity. Besides their differential domain structure, 
MMPs can be principally divided into secreted and membrane anchored proteinases. 
The MMP catalytic site contains a zinc ion coordinated by three imidazole nitrogens, a glutamic 
acid side chain suitably oriented to serve as an acid-base catalyst, and a main chain carbonyl 
that acts as a critical hydrogen bond acceptor. 
The most important of these MMPs are collagenase (MMP-1), which cuts intact collagen at a 
single site; gelatinases (MMP-2 and MMP-9), which degrade partially denatured collagen 
(gelatin); and stromelysin (MMP-3), which degrades multiple protein substrates in the ECM. 
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2.4.3.4. The cysteine-switch 
ProMMPs are kept in a catalytically inactive state by the interaction between the thiol of the 
conserved prodomain cysteine and the zinc ion of the catalytic site. For a proMMP to become 
catalytically active, the thiol–Zn2+ interaction must be disrupted. Van Wart and Birkedal-Hansen 
[74] proposed this process as a general and required step in the activation of all proMMPs, and 
they termed this mechanism the “cysteine-switch”, a name that remains valid and widely 
accepted. In essence, the thiol–Zn2+ interaction can be broken – and a latent MMP can gain 
catalytic activity – by three mechanisms (Figure 2.7).:  
• Modification of the free thiol by physiological (oxidants, disulfides, electrophiles) or 
non-physiologic compounds (alkylating agents, heavy metal ions)[75];  
• Direct cleavage of the prodomain by another proteinase, or  
• Chemical or allosteric perturbation of zymogen leading to inter or intramolecular 
autolytic cleavage of the prodomain. 
 
Figure 2.7. Activation of MMPs via the ‘cysteine-switch’ mechanism. The active site of MMPs consists of 3 
histidine (H) residues ligated to the catalytic Zn2+ (3His-Zn2+) or Ca2+ ions (not shown) within the catalytic domain.  
Potential substrates are unable to access the active site as it is blocked by the pro-domain  and  the  thiol-Zn2+  
interaction  (i.e.  Cys-S-Zn2+). MMPs  are  activated  by  modifying  or interrupting  the  thiol-Zn2+interaction  either  
chemically  by  ROS, disulfides, electrophiles, alkylating agents, heavy metal ions or physiologically by proteinases 
(such as elastase, plasmin, uPA, furin and other active MMPs) produces an  intermediate  MMP. Consequently  the  
cleavage  of the  N-terminal  pro-domain  by proteinases  or  by  autolysis  (e.g.  via  MMP  intermediate  itself)  
produces  an  active  MMP. Figure adapted from [76]. 
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2.4.3.5 MMP’s and MPO 
Myeloperoxidase (MPO), a heme enzyme released by activated neutrophils, from intracellular 
granules. This enzyme is the most abundant protein in neutrophils, accounting for up to 5% of 
their dry mass [77]. It is also present in monocytes, though at lower levels and it is an important 
source of reactive oxygen species [78]. Levels of myeloperoxidase are significantly higher in 
the tissues of pressure ulcers compared with those of acute healing wounds [79]. 
MPO protein has little bactericidal effect per se, but enzymatic reaction with H2O2 and halide 
(Cl−, Br−, I−) ions generates hypohalous acids as hypochlorous acid (HOCl), [80]. This oxidant 
is widely believed to be responsible for much of the anti-bactericidal activity of neutrophils. 
However, evidence has emerged that MPO-derived oxidants are extremely cytotoxic and react 
readily with most biological molecules contributing to tissue damage and the initiation and 
propagation of chronic inflammatory disease. Myeloperoxidase catalytic activity is a complex 
phenomenon involving two distinct pathways (Figure 2.8.). 
H2O2 +Cl− +H+→ HOCl + H2O 
 
 
 
 
 
 
Figure 2.8.  Representation of MPO redox transformations and catalytic pathways 
 
The levels of MMPs and characteristic amino acid oxidation products of myeloperoxidase are 
greatly elevated in inflammatory tissue of humans [81-84]. These observations suggest that 
HOCl production by myeloperoxidase may provide a pericellular mechanism for activation of 
latent MMPs during inflammation.   
HOCl reacts rapidly and nearly quantitatively interacts with thiols, thioethers, and amino groups 
[85, 86]. The high susceptibility of Cys residues to oxidation by HClO has important biological 
implications as this can disrupt the cellular redox balance of cells and inactivate multiple 
cellular enzymes that contain active site Cys residues. In pressure ulcers, HOCl can activate 
latent MMPs (e.g., MMP-7) via conversion of a key Cys residue in the “cysteine switch” 
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domain of pro-MMP-7 to a sulfinic acid [87]. In turn, modification of the prodomain thiol 
would disrupt the native conformation of the prodomain, allowing autolytic cleavage and 
activation. These findings suggest that HOCl production by MPO might be a physiologically 
relevant pathway for triggering MMP activation. 
In addition HOCl has important effect on the specific endogenous tissue inhibitors of MMPs 
(TIMPs). TIMPs inhibit the proteolytic activity of MMPs by forming a stable, noncovalent 1:1 
stoichiometric complex [88-90]. Importantly, all TIMPs have a conserved N-terminal sequence 
that contains Cys [88]. The N-terminal α-amino and carbonyl groups of the Cys residue 
coordinate the essential catalytic Zn2+ of the metalloproteinase indicating that Cys plays a key 
role in inhibiting MMP activity. Studies have demonstrated that the loss of TIMP inhibitory 
activity is strongly correlated with Cys oxidation by HOCl generated by MPO [91].  
In summary, the involvement of excessive production of HClO by MPO pressure ulcers 
contributes to the development of proteolytic unbalance in the wound, via two mechanisms: 
• Activating the inactive pro-forms of MMPs, 
• Impairing the ability of TIMP to regulate MMPs activity 
2.4.3.6. The microbiological environment 
There are several factors known to affect the bacterial burden of chronic wounds and increase 
the risk of infection. These include the number of microorganisms present in the wound, their 
virulence and host factors. The presence of microorganisms alone (colonization) does not 
indicate an infection in pressure ulcers. Colonization with bacteria is common and unavoidable. 
All chronic wounds become colonized, usually with skin organisms, followed in 48 hours by 
gram-negative bacteria. 
Wound infection is defined as the presence of replicating microorganisms within a wound with 
a subsequent host response that leads to a delay in healing. Because of this it is important that 
infection is recognized as early as possible. The signs and symptoms of local infection are 
redness (erythema), warmth, swelling, pain, and loss of function. Foul odor and pus may 
accompany this. Eventually, the local bacterial burden will increase further and becomes 
systemically disseminated resulting in sepsis, which if not actively treated could progress to 
multi-organ failure and death in some instances. 
The mix of microorganisms within a wound may also be an issue. Most chronic wounds are 
polymicrobial, and infections generally involve mixed populations of aerobic and anaerobic 
bacteria. [92, 93]. This is significant because some combinations of bacterial species may 
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develop synergy with each other, resulting in previously non virulent organisms becoming 
virulent and causing damage to the host [94-97]. 
The characteristics of bacteria in chronic wounds are summarized in table 2.4. 
 
Table 2.4. Feautures of bacterial environment in chronic wounds. 
High levels of bacterial content (>105 bacteria per gram tissue can cause clinical infection) 
Presence of more than one bacterial strain 
Bacteria capable of altering their phenotypic and genotypic characteristics 
Presence of multi-drug resistant organisms 
Presence of 'biofilms' 
Recurrent local and/or invasive wound infections 
 
Besides to episodes of infection, the continued presence of bacteria in a wound leads to 
endotoxin production and stimulates the host's immune defenses to produce pro-inflammatory 
mediators. Although inflammation is part of normal wound healing, the repair process may be 
prolonged if the inflammation is excessive [98]. Furthermore, with chronic colonization bacteria 
in wounds form biofilms (bacterial colonies embedded in a self-secreted extracellular 
polysaccharide matrix) that are resistant to the action of host defenses and antimicrobial agents, 
thereby contributing to delayed healing [99]. The presence of bacteria induces the immigration 
of monocytes, macrophages and leukocytes, whose inflammatory response exaggerates the 
tissue damaging processes [100, 101].  
Among all bacterial species found in infected chronic wound, recent findings pointed out to 
Pseudomonas aeruginosa and Staphylococcus aureus as main strains involved in and contribute 
to the lack of healing [102].  
S. aureus is most commonly isolated from chronic wounds [103-106] and can be found in 
superficial zones of chronic wounds and, in certain situations, can express a number of potential 
virulence factors and surface proteins which promote its adherence to the damaged tissue and 
decrease neutrophil functions and immune responses of the host [107, 108]. 
P. aeruginosa, located in the deeper regions of chronic wounds may play an important role to 
delay or even prevent the healing process [105, 106, 109]. P. aeruginosa often causes biofilm-
based chronic infections and expresses virulence factors, in particular, rhamnolipid, that can 
eliminate the activity of PMNs [110, 111]. A number of studies have demonstrated that P. 
aeruginosa is frequently present in chronic wounds [105, 111] and have provided evidence that 
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the bacteria are located in aggregates enclosed in extracellular polymeric matrix material as 
found in biofilms [111]. Furthermore, chronic wounds that harbored P. aeruginosa were larger 
than those that did not, and the healing process also seemed to be more severely hindered for 
those wounds [105, 106, 109]. 
On the other side, in addition to human MMPs, bacterial proteases have been found to be 
influential in tissue breakdown and, as such, have a role to play in the healing of infected 
wounds.  Several studies have suggested that bacterial-derived secreted proteases may act to up-
regulate the levels of MMPs produced by the host cells [112, 113]. These findings indicate that 
bacterial protease production should be taken into consideration. Thus, both host MMPs and 
those derived from infecting bacteria need to be targeted in order to increase the healing 
capacity of the injured tissue [113]. 
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2.5. Adopted strategies. Selection of the biopolymer platform 
In summary, chronic wound environment is characterized with bacterial infection and 
continuing influx of polymorphonuclear neutrophils that release high concentrations of matrix 
metalloproteases (MMPs), myeloperoxidase (MPO) and reactive oxidative species causing 
excessive degradation of the extracellular matrix (ECM) and the growth factors. In healing 
wounds the MMPs are counteracted by their natural inhibitors, while in chronic wounds the 
ratio proteases/inhibitors is disturbed and most of these enzymes are uninhibited. The protease-
antiprotease unbalance is further promoted by MPO-generated hypochlorous acid (HOCl), 
which from one side inactivates the protease inhibitors and from another triggers the activity of 
latent MMP. In addition, most chronic wounds are colonized with several bacterial species, 
predominantly Staphylococcus aureus and Pseudomonas aeruginosa that may play an important 
role to delay or even prevent the healing process. 
The development of interactive devices, that promote healing by correcting imbalances of the 
wound environment, may represent a most appropriate approach to wound healing. Hence, in 
order to improve the opportunity for wound healing, it is necessary to create conditions that are 
unfavorable to micro-organisms and favorable for the host repair mechanisms. Furthermore, the 
modulation of the proteolytic unbalance in the wound and the scavenging of ROS, are also key 
points to stop the ongoing inflammatory processes, facilitate re-epithelization, and thus support 
the healing process. 
 
Table 2.5. Performance requirements of the ideal dressing [114] 
Primary requirements 
Free of toxic or irritant extractables 
Does not release particles or non-biodegradable fibres into the wound 
Forms an effective bacterial barrier (effectively contains exudates or cellular debris to prevent 
the transmission of microorganisms into or out of the wound) 
If self-adhesive, forms an effective water-resistant seal to the periwound skin, but is easily 
removed without causing trauma or skin stripping 
Maintains the wound and the surrounding skin in an optimum state of hydration (this implies it 
is able to function effectively under compression) 
Requires minimal disturbance or replacement 
Protects the periwound skin from potentially irritant wound exudates and excess moisture 
Produces minimal pain during application or removal as a result of adherence to the wound 
surface 
Maintains the wound at the optimum temperature and pH 
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Table 2.5 (continuation) Performance requirements of the ideal dressing [114] 
Secondary requirements 
Possesses antimicrobial activity — capable of combating localised infection 
Has odour-absorbing/combating properties 
Able to remove or inactivate proteolytic enzymes in chronic wound fluid 
Haemostatic properties 
Exhibits effective wound cleansing (debriding) activity 
 
There is a large list of performance requirements of the ideal dressing summarized in table 2.5. 
Taking into consideration the biochemical chronic wound environment, and keeping these 
“ideal performance properties” in mind, this Thesis is focused in the development of chronic 
wound dressings targeting the following key properties: 
Ability to adsorb and neutralize free radicals  
Ability to balance the proteinase activity by: 
• Balance the MMP’s activity, cause of the proteolytic environment responsible of the 
ECM degradation. 
• Balance the MPO activity, responsible of: 
- Activating the inactive pro-forms of MMPs, 
- Impairing the ability of TIMP to regulate MMPs activity 
- Oxidative environment. 
• Ability to inhibit bacterial growth, spatially Staphylococcus aureus and Pseudomonas 
aeruginosa. 
To meet all these necessary requirements in a successful approach, the design of the matrices 
should be based on materials that possess the most part of required properties and capable to be 
further modified and/or implemented with active molecules to improve its healing properties. 
Natural polymer-based systems constitute an interesting alternative to produce novel wound 
dressing materials. These systems offer the advantage of being similar to biological 
macromolecules, mimicking the tissue microenvironment and stimulate appropriate 
physiological responses required for wound regeneration. Owing to their similarity with the 
extracellular matrix (ECM), natural polymers may also avoid the stimulation of chronic 
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inflammation or immunological reactions and toxicity, often detected with synthetic polymers. 
Thus the ideal biomaterial should be non-toxic, biocompatible, promoting favorable cellular 
interactions and tissue development, while possessing adequate mechanical and physical 
properties. In addition, it should be biodegradable and bioresorbable to support the 
reconstruction of a new tissue without inflammation [115, 116]. The resulting materials can be 
conjugated as membranes, hydrogels, scaffolds and microspheres to be used in specific 
biomedical applications  
Moreover the available biomaterial should require minimal processing, possess antimicrobial 
properties and promote wound healing. In recent years, a large number of research groups are 
dedicated to produce a new, improved wound dressing by synthesizing and modifying 
biocompatible materials [117]. Recent reports are also aiming on the acceleration of the wound 
repair by systematically designed dressing materials. In particular, efforts are focused on the use 
of biologically derived materials such as, chitin and its derivatives, which are capable of 
accelerating the healing processes at molecular, cellular, and systemic levels. Chitin and its 
derivative, chitosan, are biocompatible, biodegradable, nontoxic, anti-microbial and hydrating 
agents. Due to these properties, they show good biocompatibility and positive effects on wound 
healing. 
 
2.5.1 Chitosan, the biopolymer platform  
 
 
 
Figure 2.9. Molecular structure of chitosan. 
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Chitin [poly-β-(1→4)-N-acetyl-D-glucosamine] is an ubiquitous biopolymer found in the 
exoskeleton of insects, marine invertebrates and fungi and is the second most abundant 
biomaterial. Chitosan and is prepared by de-N-acetylation of chitin. Chitosan is also naturally 
present in some microorganisms and fungi.  
Chitosan is a linear is a poly-β-(1→4)-D-glucosamine (polysaccharide similar to cellulose) that 
is obtained by the partial deacetylation of chitin.  
Because chitin deacetylation is incomplete, chitosan is formally a copolymer composed of 
glucosamine and N-acetylglucosamine. It is important to note that the term “chitosan” does not 
refer to a single well defined structure, and chitosans can differ in molecular weight, degree of 
acetylation, and sequence (i.e., whether the acetylated residues are distributed along the 
backbone in a random or blocky manner). As a result of these structural differences, the 
properties of chitosan (e.g., the pKa) can also vary somewhat.  
The unique structural feature of chitosan is the presence of the primary amine at the C-2 
position of the glucosamine residues. Few biological polymers have such a high content of 
primary amines, and these amines (acetyl-D-glucosamine residues), lead to differing 
physicochemical properties and biological responses to chitosan. 
Although chitosan is insoluble in neutral or alkaline aqueous solution, it dissolves in dilute acid 
solutions, such as hydrochloric, lactic, and acetic acid. 
Due to its natural abundance and specific biological properties, chitosan is an attractive material 
for large spectra of biomedical applications including wound healing. 
 
2.5.2. Chitosan, properties for wound healing applications and 
regenerative medicine 
Compared to common polysaccharides, chitosan and chitin-based products provide improved 
healing of wounds. These healing effects can be attributed to the biochemical properties of 
chitosan and its derivatives. 
Biocompatibility  
Chitosan is reported to be biocompatible [118-123], biodegradable [121, 124-126] and of low 
toxicity [127]. Chitosan is degraded by lysozyme, and the degradation is slower, both in vitro 
and in vivo, for more highly deacetylation samples [119, 126, 128, 129]. The cytotoxicity of 
chitosan is reported to be dose-dependent and decreases with a decrease in molecular weights 
and degrees of de-N-acetylation [130]. Additionally, chitosan has partial structural similarities 
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to glycosaminoglycans, which are essential structural elements of the extracellular matrix of 
most tissues. 
Antibacterial activity 
Chitosan inhibits the growth of a wide variety of bacteria [131] (Table 2.6.). In contrast to other 
type of antibacterial products, chitosan has several advantages because it possesses a higher 
antibacterial activity, a broader spectrum of activity, a higher killing rate, and a lower toxicity 
toward mammalian cells [132]. 
 
Table 2.6.  The antibacterial activity of chitosan. Modified from [132] 
Gram-positive bacteria  (CS%, w/v) Gram-negative bacteria  (CS%, w/v) 
Staphylococcus aureus 0.05 Escherichia coli 0.025 
Corynebacterium 0.025 Pseudomonas aeruginosa 0.0125 
Staphylococcus epidermidis 0.025 Proteus mirabilis 0.025 
Enterococcus faecalis 0.05 Salmonella enteritidis 0.05 
Candida albicans 0.1 Enterobacter aerogenes 0.05 
Candida parapsilosis 0.1 
  
 
Many intrinsic and extrinsic factors can influence the antimicrobial properties, such as the 
molecular weight, degree of de-N-acetylation, microorganism species, presence or absence of 
metal cations, etc…. Also, the physical state of the chitosan can present very different 
antimicrobial properties, such as whether the chitosan is present in the form of films, hydrogels, 
coatings, in solutions or in combinations with other materials. 
Several mechanisms have been proposed for the antimicrobial activity by chitosan but the exact 
mode of action is still uncertain.  
Inhibition of MMPs [133] 
Chitosan is reported to inhibit the activation and expression of MMP2 in primary human dermal 
fibroblasts; therefore chitosan may prevent and treat several health problems mediated by 
MMP2 (that can hydrolyze the basement membrane collagen IV) such as wound healing. It was 
speculated that the inhibitory effect might be explained by the effective chelating capacity of 
chitosan for Zn2+ that would become unable to exert correctly its cofactor role in MMP2 [134, 
135]. In addition the partially hydrolyzed chitosans were found to be potent inhibitors of gene 
and protein expression of MMP9 [136, 137] that increases in the majority of malignant tumors 
and plays a major role in the establishment of metastases. 
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It is also found, that glucosamine, a constituent monomer of chitosan, inhibited the expression 
and the synthesis of MMP3 [138]. 
Wound healing properties  
Chitosan possess the characteristics favorable for promoting rapid dermal regeneration and 
accelerated wound healing. It is observed that chitosan oligosaccharides have a stimulatory 
effect on macrophages, and is chemo attractant for neutrophils in vitro and in vivo, an early 
event essential in accelerated wound healing. It stimulates cell proliferation and 
histoarchitectural tissue organization. Chitosan is a hemostat, which helps in natural blood 
clotting and blocks nerve endings and hence reducing pain [139, 140]. Chitosan can activate 
biological defense mechanisms. For example, chitosan (ca. 70% de-N-acetylated) showed 
macrophage activation and cytokine production, to initiate the healing process [141]. Chitosan 
will gradually depolymerize to release N-acetyl- β-D-glucosamine, which initiates fibroblast 
proliferation and helps in ordered collagen deposition and stimulates increased level of natural 
hyaluronic acid synthesis at the wound site [142]. At the final stage of wound healing process, 
chitosan has been demonstrated to stimulate angiogenesis, reorganization of the extracellular 
matrix and stimulating granulation tissue formation and re-epithelization [143, 144]. 
 
Figure 2.10. Schematic representation of the required properties of wound dressing material (Paul and 
Sharma, 2004). 
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Scaffold for the Regeneration of Tissue 
Chitosan provides a non-protein matrix for 3D cell proliferation and tissue growth. The 
advantage of chitosan is that it easily can be processed into multiple scaffolds (summarized in 
[140]) such as hydrogels, membranes, nanofibers, beads,  micro/nanoparticles, micropore 
scaffolds and sponges. These scaffolds can be modified to yield polymer blends, which are 
formed with desired structures, chemical features, and mechanical properties for various types 
of biomedical applications such as wound healing, tissue engineering and drug delivery.  
Chitosan chemistry 
Chitosan has a versatile chemistry due to the presence of free amino groups in the C2 positions. 
The active primary amino groups on the molecule being reactive provide sites for a variety of 
side group attachment employing mild reaction conditions. [145]. The modifications on chitosan 
provide versatile materials with specific functionality, and tunable biological and physical 
properties. 
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2.6. Summary 
With so many products coming onto the market, the difficulty is in choosing the optimum 
treatment for the requirements of each patient. As no one dressing is suitable for the 
management of all types of wounds, and few are ideally suited for the treatment of a single 
wound during all stages of the healing cycle, successful wound management depends upon a 
flexible approach to the selection and use of products based upon an understanding of the 
healing process combined with a knowledge of the properties of the various dressings available. 
Without such knowledge and careful consideration of all the factors described above, dressing 
selection is likely to be arbitrary and potentially ineffective, wasteful both in terms of time and 
physical resources. Hence, the development of new wound dressings should continue looking 
for more versatile dressings. 
Thus, the new trends in wound care research is developing  advanced  wound  care  products  to  
control  the  biochemical  environment  of  elevated  levels of MMPs, MPO, ROS and bacterial 
load  found  in  chronic  wounds. This  is because all this factors are found to  be  detrimental  to  
ECM  proteins or  factors causing  a  prolonged  inflammatory/ proliferation  phases  resulting  
in  the  development  of  chronic wounds.    
Functionalizing  chitosan platforms  with  active agents enables  the  generation  of  highly  
exclusive/specific bioresponsive  wound  dressings  to  modulate  the  biochemical  wound  bed  
microenvironment to facilitate and stimulate wound healing. 
This thesis proposes different synthetic routes to functionalize chitosan  and presents  different 
chitosan-base materials with  antioxidant, antibacterial and inhibitory capacity against wound 
enzymes  in  the  attempt of  providing  a  potential  way  of  down regulating  proteolytic 
environment of chronic wounds. 
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2.7. Objectives 
The overall aim of the present work was to develop new biomaterials capable to provide 
conditions to stimulate the chronic wound healing, as ideal candidates to further perform wound 
dressings. The specific research was defined in tree main targets: 
• Modification of chitosan based platforms to balance proteolytic activity of  MMPs  
• Modification of chitosan based platforms to balance of myeloperoxidases activity and 
oxidative environment  
• Improve the antimicrobial behavior of chitosan based platform  
These modifications were expected to modulate the proteolytic and oxidative enzymes in 
chronic wounds and exert antimicrobial protection against wound bacterial infections. 
To reach these goals the following specific objectives were define: 
1. Functionalization of chitosan platform to improve the sequestering ability over metal 
dependent enzymes (MMPs) in chronic wounds (chapter 2). MMP inactivation can be 
induced by reagents which can induce the interaction with the zinc cation in the activation site, 
modifying MMP activity. This strategy of designing MMPs inhibitor is based on the chelating 
of Zn2+ that induces inhibition of MMPs. In order to bring to chitosan the ability to inhibit 
MMP, chitosan was functionalized with deferent thiol moieties. In addition the combination of -
NH2 and -SH chemistry would allow for grafting of other active agents in further steps. 
2. Identification and evaluation of potential active agents as a chronic wound healing 
promoter (chapter 3). Polyphenols from the medicinal plant Hamamelis virginiana (Witch 
hazel) were studied for this porpoise in an integrated approach simultaneously targeting 
antioxidant activity, inhibitory effect on MPO and collagenase 
3.  Development of a new method for permanent for functionalization of chitosan platform 
with active agents from Hamamelis virginiana extracts (chapter 4). This new method will 
allow obtaining a chitosan platform covalently modified with phenolic moieties. The new 
biopolymeric material will combine the chemistry of amino, thiol and phenolic groups and is 
expected to possess enhanced antioxidant capacity and antimicrobial effect.  
4. Development of new hydrogel dressings for chronic wound application containing 
chitosan, gelatin, and natural phenolics, cross-linked by laccase reaction (chapter 5). This 
enzymatic method would allow to obtain bioactive and biostable materials with tunable 
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physicomechanical and functional properties.  At the same time,  polyphenols are expected to 
play a dual role in the hydrogel: i) “passive” – being a structural element, and ii) “active” – 
modifying the chronic wound environment by attenuating the wound enzymes, ROS activities, 
and the bacterial infection. 
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3.1. Introduction 
As is mentioned in the general introduction, the thiol group of cysteine in the propeptide 
interacts with a Zn2+ ion in the enzyme’s active site. This interaction, [Zn2+-cysteine], keeps the 
proMMP inactive [1, 2]. A mechanism known as the cysteine switch mobilizes proMMP’s 
activation [3]. With the assistance of other MMPs, the second step involves cleaving the 
propeptide, which converts the enzyme into its active form. Activation pathways vary among 
MMPs (Figure 1.8). MMP inactivation can be induced by reagents which can induce the 
interaction with the zinc cation in the activation site, modifying MMP activity. The use of thiol 
zinc-binding groups in MMP inhibitor design is largely reported. This strategy of designing 
MMPs inhibitor is based on the chelating of Zn2+ that induces inhibition of MMPs 
In order to bring to chitosan the ability to inhibit MMP, chitosan was functionalized with 
deferent thiol moieties. Therefore, various chitosan derivatives were synthesized varying the 
thiol molecule, thioglycolic acid and Trauts reagent (2-Iminothiolane HCl) and the amounts of 
immobilized thiol groups. Two types of thiolated chitosan were obtained: chitosan-cysteine 
conjugates, chitosan-thioglycolic (C-TGA) acid conjugates and chitosan-4-thio-butyl-amidine 
(C-TBA) conjugates. In all cases the primary amino group at the 2-position of the glucosamine 
subunits of chitosan is the main target for the immobilization of thiol groups (scheme 3.1). The 
resulting polymer conjugates were characterized by FTIR and the ability to inhibit collagenase 
activity was investigated. 
These modifications aimed to improve the sequestering ability of chitosan over metal dependent 
enzymes (MMPs) in chronic wounds. In addition the combination of -NH2 and -SH chemistry 
would allow for grafting of other active agents in further steps of this Thesis. 
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Scheme 3.1. Schematic representation of thiolation reaction of chitosan 
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3.2. Material and methods 
3.2.1. Thiolated with thioglycolic acid using EDAC activation 
Carboxylic acid group of thioglycolic acid (Sigma) reacts with the primary amino group of 
chitosan (KitoZyme, Belgium) mediated by a water soluble carbodiimide [4]. 
The immobilization of thiol groups on the surface of the chitosan was achieved by the covalent 
attachment of thioglycolic acid (TGA) (Sigma) to the primary amino groups of chitosan 
(KitoZyme, Belgium) via an amide bond. The coupling reaction was mediated by a 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC) [5] (Sigma). 
Chitosan was dissolved in 1% HCl to obtain 1 % final concentration. A constant proportion 1:1 
(w/w) chitosan:TGA was mixed,. Finally, different amounts EDAC were added. The pH was 
adjusted to 5 with 1M NaOH. After 3 h of incubation at room temperature under continuous 
stirring, the products were dialyzed 8 h against 5 mM HCl, two times for 8 h against 5 mM HCl 
containing 1 % NaCl, and finally 24 h against 1 mM HCl, to obtain pH5. Samples prepared in 
the same way, but omitting the addition EDAC, served as controls. Thereafter, the polymers 
were lyophilized and stored at -20 ºC under nitrogen.  
 
3.2.2. Thiolated by 2-iminothiolane hydrochloride (Traut’s reagent) 
Thiolation with 2-iminothiolane hydrochloride (Traut’s reagent) offers the advantage of a 
simple one step coupling reaction. The synthesis of chitosan-4-thio-butyl-amidine conjugate 
(chitosan–TBA conjugate) was carried out using a modification of the method developed by 
Bernkop-Schnurch et al. [6]. Chitosan was dissolved in 1 % HCl to obtain 1 % final 
concentration. The pH was adjusted to 6.5 with 2 M NaOH. Different amounts of 2-
iminothiolane HCl (Traut’s reagent) were added. After 24 h of incubation at room temperature 
under continuous stirring, the resulting chitosan–TBA conjugate was dialyzed 8 h against 5 mM 
HCl, two times for 8 h against 5 mM HCl containing 1 % NaCl, and finally 24 h against 1 mM 
HCl. A sample prepared in the same way but omitting the addition of 2-iminothiolane HCl 
served as a control. The polymers were liophylised thereafter. The degree of modification was 
monitored by a modified iodine titration method for determination of free -SH groups [7]. 
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3.2.3. Determination of free SH groups on thiolated chitosan 
The degree of thiol modification of chitosan was estimated by with Ellman’s reagent [7]. 
Briefly, each conjugate was dissolved in demineralized water final concentration of 2% (m/v). 
To aliquots (250 μl) of the conjugate solutions, 250 μl of 0.5 M phosphate buffer pH 8.0 and 
500 μl of Ellman’s reagent (dissolved in 10 ml of 0.5 M phosphate buffer pH 8.0) were added. 
The reaction was allowed to proceed for 2 h at room temperature. Afterwards, the precipitated 
polymer was removed by centrifugation and 300 μl of the supernatant fluid was transferred to a 
microtitration plate. The absorbance was immediately measured at a wavelength of 450 nm with 
a microplate reader (Infinite M200, Tecan, Austria). Nonthiolated chitosan was used as a blank. 
The amount of thiol moieties was calculated from a standard curve elaborated at the same 
conditions with cysteine–HCl solutions.  
 
3.2.4. FTIR analysis 
Infrared spectra of the samples were collected over the 3500 - 800 cm-1 range using Perkin-
Elmer Spectrum 100 (Perkin-Elmer, Massachusetts, USA) equipped with universal ATR 
sampling accessory, performing 50 scans for each spectrum.. 
 
3.2.5. Inhibition tests for proteolytic enzymes with thiolated chitosans 
The inhibitory efficiency of chitosan and thiolated chitosan on proteolytic enzymes was 
assessed against serine protease Subtilisin A from Bacillus licheniformis (EC 3.4.21.14 from 
Novozymes) as a model for elastases, and collagenase with high purity from Clostridium 
Histolyticum (EC 3.4.24.3 from Sigma) as a model of MMPs. Subtilisin A activity was 
determined on casein substrate. Fluka 27669/27671 Collagenase Chromophore-Substrate Kit 
(for quantitative Collagenase-Determination) was used to measure collagenase activity. The 
specific collagenase substrate used was 4-Phenylazobenzyl-Pro-Leu-Gly-Pro-D-Arg-OH 
dehydrate. 
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3.3. Results and discussion 
3.3.1. Characterization of functionalized chitosan 
 
Figure 3.1. (A) Amount of free SH groups in TGA-Chit conjugate by the modified iodine titration method; 
chitosan concentration 1 % (w/v), Ratio chitosan:TGA 1:1 (w/w), at 25 ºC, pH 5.0; (B) Amount of free SH 
groups present in TBA-Chitosan conjugate determined by modified iodine titration method. 
 
Good correlation between the increase of thiol groups and increase of Traut’s reagent 
concentration or EDAC was observed (Figure 3.1.).  
Thiolation was confirmed by FTIR (Figure 3.2.). The band at 1630 cm-1 attributable, in case of 
chitosan to C=O stretching of carboxylic acids and amides, increased in  case of C-TGA and C-
TBA due to the carbonyl (C=O) of thioglycolic acid and imino group (C=N) of Traut’s reagent 
respectively [8] (Fig. 2.2). At the same time the band at 1203 cm-1 attributable to C-N stretching 
of amines increases after functionalization of chitosan, pointing out the formation of new C-N 
bounds. In chitosan spectra it is observable a band at 1593 cm-1 which corresponds to NH+2 salts 
[8] that disappears after functionalization. These observations confirm functionalization of 
chitosan with thioglycolic acid and Traut’s reagent though the free amino groups. 
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Figure 3.2. FTIR spectra of A) unmodified and thiolated chitosan, B) C-TGA and C) C-TBA. 
 
3.3.2. Inhibition of collagenase 
In this study, both C-TBA and C-TBA platform improved the inhibition of collagenase activity 
when compared with unmodified chitosan, suggesting that thiol moieties are involve in the 
process of inhibition of collagenase as was expected.  
 
Figure 3.3. Inhibition of collagenase after 2 h at 25 ºC in TRIS-HCl buffer pH 7.1 with chitosan and 
thiolated chitosan conjugates; C-TGA  (thioglycolic acid : EDAC 1:2 w/w), chi-TBA (chitosan : Traut´s 5:2 
w/w) 
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3.4. Conclusions 
The functionalization of chitosan with thiol moieties implements chitosan with inhibitory 
properties against collagenase. This improvement makes this functionalized chitosan good 
candidates as a platforms to configure wound dressings. In addition the combination of -NH2 
and -SH chemistry would allow for grafting of other active agents. 
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4.1. Introduction 
Chronic wound is a complex environment characterized with the simultaneous interaction of 
elevated levels of neutrophils, neutrophil-derived proteolytic enzymes [1] and reactive oxygen 
species (ROS) [2]. MMPs, degrade components of the extracellular matrix such as elastin and 
collagen, and growth factors formed in the wound site, thereby impairing the healing [3, 4]. 
Collagenase is a matrix metalloproteinase largely present in chronic wounds [5] that specifically 
recognizes and cleaves collagen. In healthy tissues these proteases are counteracted by their 
natural inhibitors [6], while in chronic wounds the ratio of proteases to their natural inhibitors is 
biased in favor of proteases, so that most of the enzymes are uninhibited. 
The other major factor governing the protease–antiprotease balance is the generation of 
hypochlorous acid (HOCl), the most powerful neutrophil oxidant [7], by MPO. The cytotoxicity 
of this reaction allows the killing of the invading microbial pathogens. However, the HOCl 
generated also reacts with most biological molecules, including the protease inhibitors, thereby 
promoting proteolytic damage in chronic wounds. 
It could be expected that chronic wounds would start to heal as soon as the physiological 
balance, similar to that in acute wounds, is restored. This implies reducing the 
concentration/activity of protein degrading enzymes together with scavenging and/or inhibition 
of ROS in a controlled manner to encourage the healing process. Polyphenolic compounds 
present as secondary metabolites in plants have recently attracted much attention due to their 
curative properties. Their structures vary from simple molecules, such as phenolic acids, to 
highly polymerized compounds. The degree of polymerization and the chemical nature of the 
repetitive units constitute important structural features related to their physicochemical and 
biological properties. The primary effect of plant polyphenols is believed to reside in their 
antioxidant capacity and scavenging activity over both free radical and non-radical reactive 
species [8], metal-chelating capability [9] and inhibitory activity over radical-generating 
enzymes [10]. Plant polyphenols have been also reported to have anti-inflammatory [11], anti- 
microbial [12], immunomodulatory [13] and wound healing promoting properties [14] mostly 
explained by their antioxidant activity [15]. All of these benefits provided by the plant 
polyphenols could be employed in chronic wound management. 
Polyphenols from bark, twigs and leaf extracts from the medicinal plant Hamamelis virginiana 
(Witch hazel) are widely used as components of skin care products and in dermatological 
treatment of sun burn, irritated skin etc. [16]. The aim of this work was to evaluate the potential 
of a polyphenol extract from H. virginiana as a chronic wound healing promoter in an 
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integrated approach simultaneously targeting antioxidant activity, inhibitory effect on MPO 
chlorinating activity and collagenase inhibition. 
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4.2. Materials and methods 
4.2.1. Materials 
Tris(hydroxymethyl)aminomethane, cysteamine hy drochloride, tricine, taurine, acetone, acetic 
acid, ascorbic acid, Na2CO3, NaOCl (13%), KI, NaCl, NaI, CaCl2, NaOH, HCl, Zn(NO3)2 × 
6H2O, 2,2-diphenyl-2-picrylhydrazyl hydrate(DPPH), H2O2 (30%), Folin–Ciocalteu's phenol 
reagent, 3,3′,5,5′-tetramethylbenzidine (TMB), (±)6-Hydroxy-2,5,7, 8-tetramethylchromane-2-
carboxylic acid (Trolox), dimethyl sulfoxide (DMSO), (ethylenedinitrilo)tetra acetic acid 
(EDTA) and N-(3-[2-Furyl]Acryloyl)-Leu-Gly-Pro-Ala (FALGPA); HPLC standards: (−) 
+epicatechin +(EC), (+) +catechin (c), (+) +gallocatechin (GC), (−)epigallocatechin (EGC), 
(+)epigallocatechin 3+ O-gallate (EGCG), gallic acid (GA), methyl gallate (MG) and 
hamamelitannin (HT); collagenase from Clostridium histolyticum (EC 3.4.24.3) and catalase 
(EC 1.11.1.6) from bovine liver were purchased from Sigma–Aldrich (Spain). Analytical grade 
MeOH and Ethanol 96% were obtained from Panreac (Spain). Acetonitrile HPLC grade and 
trifluoroacetic acid (TFA) were purchased from Fluka BioChemika (Spain). Myelo peroxidase 
from human polymorphonuclear leukocytes was provided by Planta Natural Products (Austria). 
All chemicals used in this work were of the highest grade commercially available. Ultra-pure 
water obtained with a Milli-Q plus 185 from Milipore Ibérica S.A. (Spain) was used for all 
solutions. 
 
4.2.2. Preparation of Hamamelis virginiana extracts 
Witch hazel (Hamamelis virginiana) was provided by Martin Bauer GmbH (Alveslohe, 
Germany). The phenolic extracts were prepared according to a described methodology [16-19] 
illustrated in Scheme 4.1. Briefly, chopped stems of H. virginiana were incubated with an 
acetone/water mixture for a period of 24 h at room temperature. The solid was filtered off, and 
the acetone was evaporated at reduced pressure. The remaining solution was defatted with n-
hexane, and the oligomeric fraction was extracted with ethyl acetate. The aqueous dry fraction 
(AWH) was obtained after freeze-drying the aqueous solution. The organic phase was drying 
under vacuum, the resulting pellet was dissolved in deionized water, and the solution filtered 
through a porous plate. The organic dry fraction (OWH) was finally obtained by freeze-drying. 
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Scheme 4.1. Scheme of extraction of polyphenolic fractions from Hamamelis virginiana 
 
3.2.3. Characterization by Thiolysis with Cysteamine and RP-HPLC 
The size and composition of the phenolic compounds and the procyanidins within the fractions 
were estimated from the HPLC analysis after thioacidolytic depolymerization in the presence of 
cysteamine as previously described [20, 21]. The following conditions were used: loading 
volume 40 μL, 10 μg; elution, (A) 0.1% (v/v) aqueous trifluoroacetic acid (TFA) and (B)0.08% 
(v/v) TFA in water/acetonitrile 1:4, gradient 12–30% B over 30 min at a flow rate of 1 mL/min. 
Reverse phase high performance liquid chromatography (RP-HPLC) analysis was conducted on 
a Hitachi (San Jose, CA) Lachrom Elite HPLC system, equipped with diode array detector 
(DAD) and fitted with an analytical column (25 cm × 0.4 cm i.d., 100 Å, 5 μm particle size) 
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Kromasil C18 (Teknokroma, Spain). Detection was performed from 210 to 380 nm and 
acquisitions were examined using EZChrom Elite 3.1.3 from Scientific Software Inc. 
(Pleasanton, USA). Data were acquired in triplicate. The amount of the released moieties was 
calculated from the peak areas and compared to the calibration curves obtained with the pure 
standards. Terminal units: (+) GC, (‐)‐ EGC, (+) C, (‐)‐ EC, (‐) EGCG and (‐) ECG and (‐) 
ECG; extension units: cysteamine (Cya)-C, Cya-EC, Cya-EGC, Cya-EGCG, and Cya-ECG. The 
mean degree of polymerization (mDP) was estimated by dividing the molar amounts of total 
units by the molar amounts of the terminal units. 
 
3.2.4. The total phenolic content 
The total phenolic content in the extracts were estimated as gallic acid equivalents, according to 
the Folin–Ciocalteu's method [22].  Initially, 50 μL of sample (25 mg/mL) were mixed with 1.2 
mL of H2O and 0.25 mL of undiluted Folin–Ciocalteu's reagent. After 1 min, 0.75 mL of 20% 
aqueous Na2CO3 were added, and the volume made up to 5 mL with H2O. After 2 h of 
incubation at room temperature, the absorbance was measured at 760 nm in a microplate reader 
(Infinite M200, Tecan, Austria). Gallic acid standards were used to build the calibration curve 
and estimate the phenolic content as gallic acid equivalents. The control samples contain all the 
reaction reagents except the extract. The results are the mean values of three measurements 
 
3.2.5. Electrochemical measurements 
Electrochemical measurements were carried out using a μAutolab Type III EcoChemie, 
(Metrohm, The Netherlands) potentiostat/galvanostat controlled by Autolab GPES software 
version 4.9. All the experiments were carried out in a 20 mL Metrohm (Switzerland) cell with a 
three-electrode configuration. The working electrode was a glassy carbon (GCE) with a surface 
diameter of 3 mm (Metrohm). The counter and reference electrodes were platinum and Ag/AgCl 
electrodes from Metrohm, respectively. The renewal of the glassy carbon surface was achieved 
by polishing with 1.0 and 0.3 μm alpha-alumina (Micropolish, Buehler, USA) on a microcloth 
polishing pad (Buehler), followed by washing in an ultrasonic Selecta bath for 2 min. For the 
experiment with MPO a 5 μL sample of a 2 μM enzyme solution was dropped onto the polished 
surface of the GCE and allowed to dry for 15 min at room temperature. 
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3.2.6. Characterization of antioxidant activity of the fraction in vitro  
Radical scavenging activity of the OWH fraction was determined by measuring the decrease in 
absorbance of DPPH● radical at 515 nm [15]. Different concentrations of the OWH fraction 
were incubated with 3 mL of a DPPH● (6 × 10‐5 M) in MeOH at room temperature in dark for 
15 min. The experiment was carried out in triplicate and the results expressed as %-inhibition of 
DPPH. Trolox, a water-soluble analogue of α-tocopherol (vitamin E), was used as reference 
compound. Antioxidant activity was evaluated as the concentration required to inhibit 50% of 
DPPH radical formation (IC50). Non-radical scavenging activity was tested using hypochlorous 
acid. HOCl was measured by chlorination of taurine as previously described by [23]. The 
method quantifies the amount of taurine chloramine produced using iodide to catalyze the 
oxidation of TMB. The reaction mixture (300 μL) was prepared in 50 mM PBS pH 6.5 
containing 150 mM NaCl, 5 mM taurine, NaOCl (50 μM in HOCl) and different concentrations 
of the extract. Finally, 75 μL of the detection reagent containing TMB (2 mM) and NaI (100 
μM), in 400 mM acetate buffer pH 5.4, 10% DMSO, were added to the reaction mixture. After 5 
min, the quantity of taurine chloramine generated was measured by recording the absorbance at 
650 nm. Ascorbic acid as a potent HOCl scavenger was used as a reference. HOCl 
concentration from NaOCl solutions was determined by iodometry with a 20 mM KI solution. 
Iodine formed was measured at 350 nm and the acid concentration calculated using an 
extinction coefficient of 22 900 M‐1 cm‐1 [24]. All determinations were made in triplicate and 
expressed as %-inhibition of taurine chlorination. The concentrations required to inhibit 50% of 
taurine chlorination were also determined (IC50). 
 
3.2.7. Myeloperoxidase assay  
Peroxidase activity of MPO was evaluated using guaiacol as substrate [25]. The inhibitory 
effect of plant extracts on MPO peroxidase activity was measured in a solution containing MPO 
(13 nM), guaiacol (10 mM) and H2O2 (100 μM) in 50 mM PBS pH 6.6. After 1 min of 
enzymatic reaction the change in absorbance at 470 nm was recorded. Inhibition of 
myeloperoxidase chlorinating activity was assessed as previously described for the scavenging 
assay. The method quantifies the amount of taurine chloramine produced by the MPO/H2O2/Cl − 
.The reaction mixture (300 μL) contained the following reagents, at final concentrations stated 
between brackets, in 50 mM PBS pH 6.5, 150 mM NaCl, 5 mM taurine: MPO (13 nM), H2O2 
(100 μM) and OWH extract (0–50 μg/mL). After 2 min at 37°C, the enzymatic reaction was 
stopped by addition of 10 μL of 1 mg/mL catalase solution. Finally, 75 μL of the detection 
reagent (2 mM TMB, 100 μM NaI in 400 mM acetate buffer, pH 5.4, 10% DMSO) were added 
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to the reaction mixture. After 5 min the quantity of taurine chloramine generated during the 
enzymatic reaction was measured by recording the absorbance at 650 nm. MPO concentration 
was selected in order to produce about 60 μM of HOCl during the 2 min of the enzymatic 
reaction. All the assays were done in triplicate and the results expressed as the concentrations 
required to inhibit 50% production of HOCl by MPO (IC50). 
 
3.2.8. Zn2-binding assay  
The Zn2 + -binding assays were performed in 50 mM Tricine, 100 mM CaCl2, 400 mM NaCl, 
pH 7.5 using Zn(NO3)2 × 6H2O. EDTA solutions were prepared in 0.1 M Tris-HCl, pH 8. The 
concentration of the extract used for the spectrophotometric studies was 100 μg/mL. The direct 
determination of zinc in the electrochemical assays was carried out by differential pulse anodic 
stripping voltammetry (DPASV) on a bare GCE. The zinc ions (25 μM) were first deposited by 
reduction at ‐1.5 V during 10 s and then detected by scanning the potential from 1.5 to 0.9 V. 
 
3.2.9. Collagenase inhibition  
The collagenase activity was measured as described by [26], using FALGPA as substrate. The 
hydrolysis of FALGPA (1 mM) in 50 mM Tricine, 100 mM CaCl2, 400 mM NaCl, pH 7.5 was 
monitored at 345 nm over 5 min. Collagenase final concentration was 0.2 μg/mL. Inhibition 
studies were carried out by adding different concentrations of the extract to the collagenase 
solution and incubating for 1 h at 25°C. The reaction was then initiated by addition of FALGPA 
substrate. All the assays were done in triplicate and the results expressed as the concentration 
required to inhibit 50% hydrolysis of FALGPA by collagenase (IC50). 
To determine the kinetics of collagenase inhibition, the experiment above was repeated for 
different collagenase concentrations. The kinetic parameters were calculated from Eisenthal-
Cornish-Bowden plot and secondary plots of Kmapp/Vmaxapp vs [I] and 1/Vapp vs [I]. 
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4.3. Results and discussion 
4.3.1. Characterization of H. virginiana fraction  
The total phenol content of the OWH and AWH fraction was determined by the Folin–Ciocalteu 
method, and expressed as milligrams of gallic acid per gram of extract (EGA/g). The mean 
degree of polymerization and galloylation of the condensed tannin portion (monomers + 
proanthocyanidins) of both fractions was estimated by thioacidolysis in the presence of 
cysteamine. The fraction contained flavanol (catechin) monomers, proanthocyanidins and 
hydrolysable tannins (Figure 4.1 and 4.2). The structures of the major compounds found in the 
H. virginiana fraction are depicted in Table 4.1. OWH was rich in monomeric flavanol units, 
showing degree of polymerization (1.4) meanwhile AWH was rich in oligomeric structures 
(degree of polymerization 6.2)  similar to that previously reported [21]. 
 
 
Figure 4.1. Chromatogram of OWH fraction after thiolation with cysteamine The characterization was 
performed in  Lachrom Elite HPLC, photodiode array UV detector, column Kromasil C18 Teknokroma, 
Load, 40 μL, 10 μg; elution, [A] 0.1% (v/v) aqueous TFA and [B] 0.08% (v/v) TFA in water/CH3CN 1:4, 
gradient 12-30% B over 30 min, flow rate 1mL/min. The inset shows the percentage of the main 
components of the plant extract.  * GAE (gallic acid equivalents) 
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Figure 4.2. Chromatogram of AWH fraction after thiolation with cysteamine The characterization was 
performed in  Lachrom Elite HPLC, photodiode array UV detector, column Kromasil C18 Teknokroma, 
Load, 40 μL, 10 μg; elution, [A] 0.1% (v/v) aqueous TFA and [B] 0.08% (v/v) TFA in water/CH3CN 1:4, 
gradient 12-30% B over 30 min, flow rate 1mL/min. The inset shows the percentage of the main 
components of the plant extract.  * GAE (gallic acid equivalents) 
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Table 4.1. Structures of the main polyphenolic compounds found in the OWH and AWH fraction 
 
 
As the composition of OWH was richer in phenolics, it was chosen to perform the followed 
study for further chitosan modification described in Chapter 6, meanwhile AWH fraction as it 
was richer in oligomeric phenolics it was chosen to chitosan modification described in Chapter 
5. 
The total antioxidant capacity of the OWH fraction was evaluated in terms of scavenging effect 
over DPPH radical and HOCl acid (Figure 3.3). The results indicate that the reference 
compound Trolox was a more efficient (IC50 = 6.6 ± 0.3 μg/mL) DPPH radical scavenger than 
the OWH fraction (IC50 = 10.7 ± 0.7 μg/mL). However, both OWH and Trolox at concentrations 
of 20 μg/mL reached 90% of DPPH inhibition. 
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Figure 4.3. Antioxidant activity of OWH fraction in terms of: (A) free-radical and (B) non-radical scavenging 
activity. 
The hypochlorous acid (50 μM) scavenging activity of OWH was slightly higher than that of 
ascorbic acid used as a reference, with IC50 values of 2.7 ± 0.1 and 3.3 ± 0.1 μg/mL 
respectively. These results clearly indicate that OWH fraction is an efficient scavenger of 
radical and non-radical reactive species. 
 
4.3.2. Myeloperoxidase inhibition  
A simplified mechanism of MPO catalytic cycle is shown in Figure 4.4. In the presence of 
H2O2, the ferric (FeIII)-form of MPO is oxidized by a two-electron equivalent to the redox 
intermediate compound I. This compound is a strong oxidant mediating both one- and two-
electron oxidation reactions. Depending on the substrate availability, the enzyme follows either 
the halogenation or the peroxidase cycle. The halogenation cycle is a direct two-electron 
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reduction of compound I to the native form of the enzyme. In the peroxidase cycle, compound I 
is reduced in a two-step one-electron sequential reaction via formation of compound II. Many 
inorganic and organic substrates have been found to act as electron donors for compounds I and 
II. The principal reaction catalysed by MPO under physiological conditions is the oxidation of 
Cl − to the corresponding hypochlorous acid. This acid is a strong chlorinating oxidant and is 
able to initiate modification reactions affecting lipids, DNA and (lipo)proteins. The inhibition of 
MPO chlorination activity could be envisaged at different levels including: (i) diversion of MPO 
from the chlorination cycle, and (ii) application of HOCl scavengers. Thus, in addition to the 
HOCl-scavenging ability of the OWH, the phenolic extract should be evaluated as a substrate 
for the peroxidase cycle of MPO as well. As a high concentration of scavengers is usually 
required to be effective, diversion of the enzyme from the chlorination cycle, suppressing 
excessive HOCl production, might be a suitable alternative. Furthermore, different phenolic 
compounds have already been reported to be MPO peroxidase substrates [27]. 
 
Figure 4.4. MPO catalytic cycle. 
 
Figure 4.5A shows cyclic voltammograms of OWH in the presence and absence of MPO. The 
irreversible oxidation peak (Epa) at 250 mV in the cyclic voltammogram of OWH alone is 
related to the oxidation of phenols present in the extract. An important decrease in the anodic 
peak current was observed in the presence of MPO. This was due to the catalytic but not 
electrodic oxidation of the polyphenols from the OWH fraction. If these compounds were 
oxidized by MPO, a decrease in the oxidation current would be expected. 
In order to verify whether OWH polyphenols are peroxidase substrates for MPO, their 
inhibitory effect on MPO peroxidase activity using guaiacol as a substrate was studied (Figure 
4.5B). The decrease of the absorbance at 470 nm, where guaiacol oxidation products show their 
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maximum absorption in the presence of different concentrations of polyphenols (IC50 = 7.6 ± 
0.4 μg/mL), confirmed the ability of the OWH extract to act as a peroxidase substrate for MPO. 
Once the role of the OWH extract in the peroxidase cycle was established, the effect of this 
extract on MPO chlorination was studied. The halogenation activity of MPO was determined by 
measuring the chlorination of taurine with a MPO/H2O2/Cl‐ system. For this assay the MPO 
concentration was calculated in order to produce about 60 μM of HOCl after 2 min of enzymatic 
reaction in the presence of 150 mM Cl‐. The OWH extract inhibited taurine chlorination 
mediated by the MPO/H2O2/Cl‐ system in a dose- dependent manner (data not shown), giving 
50% inhibition (IC50) for 1.3 ± 0.1 μg/mL of the extract. This IC50 value, lower than the value 
previously calculated for HOCl-scavenging activity, confirms that plant extracts with moderate 
scavenging activity were able to inhibit the HOCl production by MPO. 
To understand the mechanism by which plant polyphenols were able to suppress the generation 
of HOCl, the changes in the absorption spectrum of MPO during enzyme turnover in the 
presence or absence of the extract were studied. Changes in the MPO spectrum can be followed 
by monitoring the absorbance between 390 and 600 nm where both the native form of the 
enzyme (430 nm) and compound II (456 nm) have their maximum absorption. As shown in 
Figure 3.4C, the native form of MPO (peak at 430 nm) was observed when the substrate was a 
chloride anion, since the redox intermediate compound-I reacts rapidly with the chloride- 
generating HOCl. However, the addition of a competitor substrate such as OWH extract to the 
reaction mixture promoted the formation of compound II (peak at 456 nm), which is unable to 
catalyze the production of HOCl. Therefore, the polyphenols from H. virginiana are not only 
scavengers of HOCl but can also serve as substrates in the MPO peroxidase cycle, thereby 
diverting the enzyme from its chlorination activity. 
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Figure 4.5. OWH myeloperoxidase inhibition. (A) Cyclic volta mmograms of 12 μg/mL of OWH in the 
absence (thin line) and presence (thick line) of MPO. 50 mM PBS pH 6.5, H2O2 100 μM and MPO 2 μM. 
Scan rate 5 mV/s. (B) Effect of OWH on MPO peroxidase activity. MPO 13 nM, guaiacol 10 mM and H2O2 
100 μM in 50 mM PBS pH 6.6. Enzymatic reaction time 1 min. (C) Effect of OWH on the absorption 
spectrum of MPO. 50 mM PBS pH 6.5, 150 mM NaCl, H2O2 30 μM, MPO 1 μM and 7.5 μg/mL OWH. 
Spectra were recorded at 30 s. 
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4.3.3. Collagenase inhibition  
Chronic wounds are known to contain elevated levels of matrix-degrading enzymes including 
proteases, glycosidases and several matrix metalloproteinases (MMPs) such as collagenases 
(MMP-1, MMP-8 and MMP-13), gelatinases (MMP-2, and MMP-9) or stromelysins (MMP-3, 
MMP-10 and MMP-11). Collagenases were the first MMPs to be discovered. This family of 
zinc-proteins is able to hydrolyze triple helical regions of collagen under physiological 
conditions. As in all MMPs, the collagenases contain a catalytic Zn2+ ion coordinated in their 
active center by three His residues. It is reported that some collagenase inhibitors bearing Zn2+ 
binding groups attack the zinc site in the catalytic domain of the enzyme [28]. 
 
 
Figure 4.6. Zn2+ -binding capacity of OWH extract. (A) Absorption spectra for 100 μg/mL OWH after 
addition 1 mM Zn2+ and 1 mM EDTA; (B) DPASV of 25 μM Zn2+ in presence of different concentrations of 
OWH ranging from 0 to 15 μg/mL. 
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The ability of the OWH extract to chelate Zn2+ ion was studied by both electrochemical and 
spectrophotometric assays. Polyphenols such as tannic acid have been previously reported to 
have Zn2+ -binding properties [29]. The UV–Vis spectra of the OWH extract (Figure 4.6A) 
shows a maximum absorbance in the region 250–300 nm. With the addition of Zn2+, an 
additional band at 300–350 nm that is related to Zn2+ -polyphenol complex formation was 
found. This band disappears, and the spectrum returns to the initial one in the presence of 
EDTA, a stronger zinc chelator than the polyphenolic compounds. The interaction between Zn2+ 
and OWH extract was also confirmed by electrochemical measurements. As Figure 4.6B shows, 
the addition of OWH to Zn2+ solution results in a decrease in the peak current recorded by 
DPASV, which fact suggests the formation of a Zn2+ -polyphenol complex. 
 
 
Figure 4.7. Collagenase inhibition by OWH.  Assayed at different FALGPA concentrations, 0.2 μg/mL 
collagenase in 50 mM Tricine, 100 mM CaCl2, 400 mM NaCl, pH 7. 
 
The inhibitory effect of different concentrations of the OWH extract on FALGPA hydrolysis 
catalyzed by collagenase was evaluated. FALGPA is a short peptide, N-[3-(2-Furyl)acryloyl)]-
Leu-Gly-Pro-Ala that can be used as synthetic substrate for collagenase activity [26]. The effect 
of OWH fraction on the hydrolysis of FALGPA by collagenase is shown in Figure 4.7. 
FALGPA hydrolysis is clearly suppressed in the presence of H. virginiana extract (IC50 = 75 ± 
10 μg/mL). However, this inhibition was not reversed by the addition of Zn2 + as reported for 
other collagenase inhibitors [30]. This suggests that the major mechanism for inhibition of 
collagenase by the OWH extract was other than Zn2 + chelation. The inhibitory effect on 
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collagenase activity of green tea polyphenols—catechin (C) and epigallocatechin gallate 
(EGCG), has been recently reported [31]. Induced conformational changes in the collagenase 
secondary structure after treatment with the green tea polyphenols were assigned as the main 
reason for enzyme inhibition. 
The direct-linear Eisenthal-Cornish-Bowden plot (Figure 4.8) describing the kinetics of 
Collagenase inhibition by extract revealed a mixed-type inhibition mechanism. 
 
Figure 4.8. Direct-linear Eisenthal-Cornish-Bowden plots of the inhibition of ChC at various fixed concentrations of 
PA with FALGPA as a substrate. The enzyme (0.2 µg/mL) was incubated in 0.05 M Tricine buffer pH 7.5 (with 0.4 
M NaCl and 0.01M CaCl2, at 37 °C for 3 h) in presence of different PA concentrations. The reaction was initiated by 
addition of four different concentrations of FALGPA for each concentration of PA and the decrease of absorbance at 
324 nm was monitored during 5 min to detect FALGPA hydrolysis products. The results represent mean values of 
three replicates. 
 
The kinetic Collagenase-OWH dissociation constant (Kic) and Collagenase-FALGPA-OWH 
dissociation constant (Kiu) (Cornish-Bowden notation) were calculated by secondary plots of 
Kmapp/Vmaxapp vs [PA] and 1/Vapp vs [PA] and the Kic and Kiu values obtained were 
6.1580 mM and 0.3904 mM respectively. These data suggest that the OWH bind both to 
Collagenase and the Collagense–FALGPA complex probably promoting conformational 
changes in the enzyme structure and inhibiting its activity [32]. The inhibitory effect on 
collagenase activity of green tea polyphenols—catechin (C) and epigallocatechin gallate 
(EGCG), has been recently reported [31]. Induced conformational changes in the collagenase 
secondary structure after treatment with the green tea polyphenols were assigned as the main 
reason for enzyme inhibition. Mixed-type inhibition may be considered as a consequence of the 
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presence of different phenolic compounds in Hamamelis virginiana extract exerting  different 
inhibition effects [31-33].  
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4.4. Conclusions 
Nowadays, the treatment of chronic wounds remains a major burden and drain on healthcare 
resources. Plant polyphenols from H. virginiana were found to have both a strong antioxidant 
activity and an inhibitory effect on MPO and collagenase – features potentially beneficial for the 
wound healing process. The extract used in this work showed a multifunctional antioxidant 
capacity. H. virginiana polyphenols were able to scavenge radical and non-radical species such 
as HOCl. Furthermore, their ability to act as peroxidase substrate for MPO results in inhibition 
of the chlorination activity of the enzyme, responsible for the HOCl production. Plant 
polyphenols also caused inhibition of the proteolytic activity of collagenase. As chronic ulcer 
fluids contain elevated levels of ROS and neutrophil-derived deleterious oxidative and 
proteolytic enzymes, the application of extract from H. virginiana seems to be a promising 
approach for use in the management of chronic wounds. 
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5.1. Introduction 
 
Chemical degradation methods for analysis of complex natural polymers such lignins and 
proanthocyanidins (PA) provide important compositional and structural information. These 
methods include among others acidolysis, thioacetolysis, hydrogenolysis, and the used in this 
paper thioacidolysis [1-3]. As an analytical method, thioacidolysis, alone or coupled with high-
performance liquid chromatography (HPLC), has been used to characterize and quantify 
proanthocyanidins in plants and fruits [3]. The reaction, based on the lability of the 
interflavonoid linkages of PA in acid conditions and in presence of excess of nucleophile in the 
medium, results in the release of terminal subunits as flavan-3-ol monomers and extension 
subunits as electrophilic flavan-3-ol intermediates. The electrophilic intermediates are trapped 
by the nucleophile to give relatively stable derivates [4, 5]. Examples of suitable nucleophiles 
are: toluene-α-thiol (benzylmercaptan or phenylmethanethiol), from which the reaction was 
named “thioacidolysis”, phloroglucinol,[2] and cysteamine [6]. 
Recently, Torres et al. adapted this analytical method to synthesize new bio-based antioxidant 
compounds by depolymerization of plant-phenolic extracts in the presence of cysteamine and 
cysteine nucleophiles [3, 7-12]. The flavan-3-ol - thiol conjugates resulting from this reaction 
showed higher antiradical capacity [7, 8] and enhanced penetration through biological 
membranes [13] compared to their underivatized counterparts.  
The depolymerization of proanthocyanidins in presence of macromolecular nucleophiles, such 
as chitosan, has never been used for permanent functionalization of biopolymers with phenolic 
moieties.  Incorporation of natural antioxidant phenolic compounds from plant extracts onto 
chitosan have been reported by using tyrosinase [14] peroxidase [15] and laccase enzymes 
resulting in significant product oxidation [16]. The incorporation of natural antioxidant, e.g., 
gallic acid and (+)catechin, by free radical grafting [17, 18], or simply by adsorption onto 
chitosan resulted in high phenolics release and a rapid decrease of the antioxidant properties of 
the chitosan-phenol complex [19]. 
Here, for the first time, the analytical thioacidolysis reaction has been used to covalently graft 
phenolic moieties on a previously thiolated chitosan in order to generate bioactive materials for 
medical applications. Thiolated chitosan was selected as a suitable polysaccharide platform 
based on its biodegradability, biocompatibility, intrinsic antimicrobial activity, and lack of 
toxicity [20-22], in addition to its chemical structure providing the necessary to perform the 
reaction nucleophilic moieties. Furthermore, the presence of thiol groups significantly improves 
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the mucoadhesive and permeation properties of chitosan [23], whereas the in situ gelling 
properties of thiolated chitosan at physiological pH are particularly interesting for wound 
dressing materials [24]. The introduction of antioxidant phenolic compounds into the structure 
of chitosan will further broaden the range of potential medical applications of this biopolymer. 
The usefulness and efficiency of the developed material was evaluated against major factors 
governing the chronicity in wounds, e.g. matrix metalloproteinases (MMPs), myeloperoxidase 
(MPO), reactive oxygen species (ROS) and bacteria contamination.  
The functionalization of thiolated chitosan was carried out with flavan-3-ols from witch hazel 
(Hamamelis Virginiana) extract. Witch hazel phenolics - proanthocyanidins and hydrolysable 
tannins - were able to protect red blood cells from free radical-induced hemolysis and inhibited 
the proliferation of tumoral SK-Mel 28 melanoma cells and HT29 and HCT116 human colon 
cancer cell lines. Moreover, this extract showed to be an effective protector against DNA 
damage triggered by hydroxyl radicals [11, 25], and exert an inhibitory effect over deleterious 
chronic wounds enzymes [26]. The method for permanent functionalization of chitosan 
developed in this paper is expected to combine the chemistry of amino, thiol and phenolic 
groups for obtaining biopolymer material with enhanced antioxidant capacity, antimicrobial 
effect and capability to modulate deleterious wound enzymes activity 
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5.2. Materials and methods 
5.2.1 Materials 
Chitosan from Agaricus bisporus (DA: 13%, MW: 50.7 KDa) was provided by KitoZyme 
(Herstal, Belgium). Witch hazel (Hamamelis virginiana) was purchased from Martin Bauer 
GmbH (Alveslohe, Germany). Ellman’s reagent (5,5′-dithiobis(2-nitrobenzoic acid), 2-
iminothiolane (TBA), gallic acid (GA), and chitosanase from Streptomices griseus were from 
Sigma-Aldrich (Spain). Collagenase from Clostridium histolyticum (1676 U/mg solid, 1 U 
hydrolyses 1.0 μmol of FALGPA per minute at pH 7.5 and 25 ºC in the presence of Ca2+) and 
N-(3-[2-Furyl]Acryloyl)-Leu-Gly-Pro-Ala (FALGPA) collagenase substrate from Sigma-
Aldrich (Spain) were used. Myeloperoxidase (MPO) from human leukocytes (1550 U/mg solid: 
1 U will produce an increase in absorbance at 470 nm of 1.0 per minute at pH 7.0 and 25 °C, 
calculated from the initial rate of reaction using guaiacol as a substrate) comes from Planta 
Natural Products (Austria). All other reagents used were of the highest grade commercially 
available from Sigma-Aldrich. 
5.2.2 Extraction of proanthocyanidins from H. virginiana 
Proanthocyanidins-rich fraction was extracted from witch hazel (H. virginiana) as previously 
reported in Chapter 4. The used extract for this experiment was AWH, rich in oligomeric 
proanthocyanidins and hydrolysable tannins (Table 5.1). Its degree of polymerization was about 
6.23 estimated by thiolytic depolymerization and high performance liquid chromatography 
(HPLC) using appropriate molecular standards (Chapter 4).  
 
Table 5.1. Polyphenolic composition of AWH witch hazel extract 
Phenolic compounds Percentage 
Catechins ( catechin and epicatechin) 17.8 
Gallocatechins ( gallocatechin, epigallocatechin) 14.5 
Catechingallates ( epigallocatechin gallate, epicatechin 
gallate) 25.5 
Hydrolizable tannins 42.2 
Total phenol content (mg GAE/g fraction) 261±10 
 
5.2.3. Thiolation of chitosan 
The incorporation of thiol groups in chitosan was carried out following the procedure developed 
by Bernkopf-Schnürch et al. [27]. Briefly, chitosan was dissolved in HCl (1% v/v). Different 
amounts of 2-iminothiolane HCl (Traut’s reagent) (Table 5.2) were added and the pH was 
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adjusted to 6 with 5 M NaOH.The reaction mixture was stirred for 24 h at room temperature. 
The resulting thiolated polymer was dialyzed against different aqueous media in the following 
order: i) 5 mM HCl, ii) twice against 5 mM HCl containing 1% NaCl, iii) 5 mM HCl, and 
finally iv) 1 mM HCl. Thereafter, the chitosan thiol derivatives, as specified in Table 2, were 
freeze-dried. The degree of thiol modification of chitosan was estimated spectrophotometrically 
using Ellman’s reagent [28]. The samples were dissolved in mQ water at final concentration of 
1 mg/mL. 
Aliquots (250 μL) of the solutions, 250 μL 0.5 M phosphate buffer pH 8.0, and 500 μL Ellman’s 
reagent (dissolved in 10 mL 0.5 M phosphate buffer pH 8.0) were reacted. The reaction was 
allowed to proceed for 2 h at room temperature. Thereafter, the polymer was removed by 
centrifugation, and 300 μL of the supernatant were transferred to a microtitration plate. The 
absorbance was immediately measured at 450 nm with a microplate reader Infinite M200, 
Tecan, Austria. Non-thiolated chitosan was used as a blank. The amount of thiol moieties was 
calculated from a standard curve obtained with cysteine–HCl solutions.  
 
Table 5.2. Thiolated chitosan samples  
Thiolated chitosan  
Sample Reaction ratio 
µmols free SH/g polymer 
code Chitosan:Traut's 
C 1:00 0.00 
C-TBA.1 10:01 21.10 ± 0.32 
C-TBA.2 2:01 140.00 ± 3.48 
 
5.2.4. Incorporation of flavan-3-ol moieties from Hamamelis virginiana 
onto chitosan via thiolysis  
A modified thiolysis procedure adopted from Selga and Torres [6] was used to obtain phenolics-
loaded chitosan. Samples of chitosan with different degree of thiolation (table 2) were dissolved 
in MeOH:H2O:HCl (43:55:2), then the H. virginiana extract was added at final concentration of 
0.3 mg/mL. The reaction was carried at 80 ºC for 15 min.  After cooling, the solutions were 
dialyzed several times at room temperature against distilled water and then freeze-dried. The 
controls were obtained submitting the same samples to thiolysis reaction at room temperature 
(RT). The samples are specified in Table 5.3. 
 
Chapter 5              A new approach to produce plant antioxidants-loaded chitosan for medical applications 
5.2. Materials and methods 
101 
 
Table 4.3.  Samples of thiolated chitosan covalently loaded with phenolic moieties.  
Sample code 
Initial conditions 
Initial sample Reaction temperature  PA (mg/mL)  
C-PA C 80 ºC 0.3 
C-TBA.1-PA C-TBA.1 80ºC 0.3 
C-TBA.2-PA C-TBA.2 80ºC 0.3 
C-PA-RT C RT 0.3 
C-TBA.1-PA-RT C-TBA.1 RT 0.3 
C-TBA.2-PA-RT C-TBA.2 RT 0.3 
5.2.4.1. Determination of the total phenolic content  
The total phenolic content of the samples dissolved in mQ water was determined 
spectrophotometrically (Infinite M200, Tecan, Austria) at 280 nm and expressed in gallic acid 
equivalents (GAE) using the equation obtained from the calibration curve performed with gallic 
acid in the same conditions.  
5.2.4.2. FTIR characterization  
Infrared spectra of the samples were collected over the 3500 - 800 cm-1 range using Perkin-
Elmer Spectrum 100 (Perkin-Elmer, Massachusetts, USA) spectrophotometer equipped with 
universal Attenuated Total Reflectance (ATR) sampling accessory, performing 50 scans for 
each spectrum.  
5.2.4.3. NMR analysis 
1H NMR analyses were carried out on a Bruker Avance III 500 MHz spectrometer (600MHz) at 
298 K. 
5.2.4.4. HPLC characterization  
Previous to the analysis the C-TBA.2-PA sample was incubated in acetate buffer (0.1 M, pH 6) 
containing 5 U of chitosanase, at 37 ºC, under continuous shaking. After 24 h of incubation 
another 5 U of enzyme were added and the reaction mixture was further incubated for 24 h.  
Then, it was centrifuged using Vivaspin 3000 MWCO (Sartorius Stedim Biotech S.A.) in order 
to separate the enzyme and non-hydrolyzed sample from the hydrolyzed oligomers. The 
resulting solution was lyophilized and re-dissolved in 0.005 M H2SO4 in mQ water to obtain 
solutions with defined concentration prior to the HPLC analysis. The HPLC analysis of the 
products of the enzymatic degradation of C-TBA.2-PA was carried out with HPLC-Agilent 
Technologies 1200, equipped with diode array detector (DAD, Agilent Technologies 1200) and 
refractive index detector (RID, Agilent Technologies 1200) coupled to a Bio-Rad aminex HPX-
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87 H column using constant flow rate of 0.6 mL/min with isocratic elution of 0.005 M H2SO4 as 
mobile phase, at 100 µL injection volume. 
 
5.2.5. In vitro tests to evaluated biological activities  
5.2.5.1. Radical scavenging activity 
The radical scavenging activity was determined spectrophotometrically measuring the decrease 
in absorbance of 1,1-diphenyl-2-picrylhydrazyl radical (DDPH) at 515 nm [29]. To measure the 
DPPH scavenging effect, chitosan and functionalized chitosans were dissolved in mQ H2O, then 
200 μL of the polymer solution were added to 1400 μL 6x10-5 M DPPH solution in MeOH, and 
incubated at room temperature in the dark for 15 min. All experiments were carried out in 
triplicate and the results are expressed as a percentage of DPPH inhibition. 
5.2.5.2. Antimicrobial test 
The minimum inhibitory concentration (MIC) of chitosan and/or modified chitosan was 
determined by a turbidimetric method [30] against Pseudomonas Aeruginosa and 
Staphylococcus aureus. The positive control was obtained with doxycycline. The samples were 
studied for visible signs of growth or turbidity. The lowest concentration of chitosan and/or 
modified chitosan that inhibited the growth of bacteria was considered as the minimum 
inhibitory concentration (MIC). 
5.2.5.3. MPO inhibition 
The inhibitory effect of the blends over MPO activity was measured using guaiacol as a 
substrate [31]. Samples were incubated with 20 µL of MPO 0.325 µM (0.60 U) and 30 µL of 
guaiacol (167 mM) buffered with 450 µL PBS pH 7.4 at 37 °C. After 3h incubation time 200 
µL of the solution were placed in a 96-well microplate and the reaction was started by adding 22 
µL of 1 mM H2O2. The change in absorbance at 470 nm was monitored during 5 cycles of 15 
sec (75 sec.) using microplate reader Infinite M200 (Tecan, Austria). All measurements were 
carried out in triplicate and the activity was determined by the rate of absorbance increase per 
min and expressed as a percentage of enzyme inhibition compared to the control (MPO reaction 
mixture without sample). 
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5.2.5.4. Collagenase inhibition 
The collagenase activity was measured using FALGPA substrate [32]. The Collagenase was 
incubated in presence of samples for 3h of incubation. The hydrolysis of FALGPA with 
collagenase 0.2 µg/mL in 50 mM Tricine, containing 100 mM CaCl2 and 400 mM NaCl, pH 7.4 
was monitored spectrophotometrically at 345 nm during 5 min, immediately after mixing the 
substrate with the enzyme. All measurements were carried out in triplicate. The results were 
expressed as a percentage of enzyme inhibition compared to the control (collagenase raction 
mixture without sample). 
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5.3. Results and discussion 
5.3.1 Functionalization of thiolated chitosan with flavan- 3-ol via thiolysis 
reaction.  
Reacting thiolated chitosan (C-TBA) with proanthocyanidins of Hamamelis virginiana in acidic 
condition was expected to yield chitosan covalently functionalized with phenolic moieties (C-
TBA-PA). Under acidic conditions, oligomeric proanthocyanidins depolymerize and the 
electrophilic intermediates can be trapped by a nucleophile through the C4 position in flavan-3-
ol (Scheme 5.1). Both amino groups of chitosan and the amidine substructure of thio-buthyl-
amidine moiety of thiolated chitosan (C-TBA) are protonated in acidic medium, thus, only the 
thiol groups can act as nucleophiles reacting with the electrophilic PA intermediates via 
thioether bonds. Therefore, the thiolysis reaction provides selective functionalization of 
thiolated chitosan through thioether linkages in a single step approach.  
 
 
Scheme 5.1. Scheme of the thiolysis reaction of proanthocyanidins (PA) in presence of thiolated chitosan 
 
Unmodified chitosan, C-TBA.1 and C-TBA.2 sample were reacted with the same amount of PA 
extract (0.3 mg/mL) at 80 ºC for 15 min. The results showed that the amount of grafted 
polyphenols via thiolysis on the thiolated chitosan increased depending on the degree of 
thiolation of the biopolymer (Figure 5.1). Polyphenols were also detected on the non thiolated 
chitosan (C-PA) possibly due to electrostatic interactions with the positively charged amino 
group of chitosan, additional hydrogen-bonds between phenolic groups and chitosan network, 
and hydrophobic interaction [19].  
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Selga et al. [33] observed that the increase of the temperature boosts thedepolymerization 
reaction. Accordingly, we carried out the thiolysis both at room temperature (RT) and at 80 ºC. 
When the reaction was carried out at RT the amount of phenolics was similar on all chitosan 
samples regardless of their thiol content, while at 80 ºC a nearly 3-fold increase of the amount 
of polyphenols on the thiolated chitosan was observed (Figure 5.1). The results showed that the 
interaction between flavan-3-ol moieties and thiolated chitosan increased with the increase of 
the thiolation degree at temperatures favoring the PA depolymerization. The sample with 
highest degree of functionalization C-TBA.2-PA was selected for further experiments. 
 
  
Figure 5.1. Amount of phenolics incorporated on thiolated chitosan as a function of the degree of thiolation 
and the reaction temperature. 
 
The band at 1630 cm-1 characteristic for C=O stretching of carboxylic acids and amides in the 
FTIR spectra of chitosan increased in  the case of C-TBA.2 and C-TBA.2-PA due to the imino 
group (C=N), which absorption peak is close to the carbonyl (C=O) stretching region [34] 
(Figure 5.2). At the same time the band at 1203 cm-1 assigned to C-N stretching of amines 
increased after functionalization of chitosan, pointing out the formation of new C-N bounds.  In 
the chitosan spectra a band at 1593 cm-1 was observed corresponding to NH3+ salts that 
disappeared after thiolation. These observations confirm the incorporation of Traut’s reagent 
though the amino groups of chitosan. In addition the band at 1540 cm-1 in C-TBA spectra 
shifted to 1522 cm-1 in C-TBA-PA spectra. This band corresponds to N-H of secondary amides 
suggesting non-covalent interactions between secondary amides of chitosan and PA. These 
expected non-covalent interactions were also observed in Figure 4.1 when the thiolysis reaction 
was conducted at RT. The absorption of the thiol group is the only peak that can be considered 
to determine the thioether linkage. Unfortunately, the equivalent C-S and C-S-H stretching 
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vibrations tend to give rise to a very weak absorption in the region of 2600 - 2550 cm-1 for S-H 
stretching and 715 – 630 cm-1 for C-S stretching [34]. Consequently, the information provided 
by the FTIR analysis revealed not to be suitable for identification of the thioether bond.  
 
Figure 5.2. Normalized FTIR spectra of freeze-dried C, C/-TBA.2 and C-TBA.2-PA samples. 
 
The 1H NMR spectra of non-functionalized chitosan (Figure 5.3A) shows characteristic peaks of 
the glucosoamine residues at 4.65 ppm for the anomeric proton on C-1, and at 2.91 ppm for the 
proton on C-2. The peak for the methyl protons of the N-acetylglucosamine residues appears at 
2.07 ppm, and the peaks between 3.4 and 4.1 ppm correspond to protons on C-3, C-4, C-5, and 
C-6. The C-TGA.2 showed new peaks at 2.77 ppm, 2.57 ppm, 2.45 ppm, and 1.97 ppm (Figure 
5.3B) assigned to the thio-buthyl-amidine, thereby confirming the thiolation of chitosan.  The 
peaks at 7.02 ppm and 7.12 ppm belong to phenyl proton signals [8] confirming the presence of 
phenolic moieties in C-TBA.2-PA structure (Figure 5.3C). The resonance signal at 2.89 ppm of 
the adjacent to thiol group protons for C-TBA.2 was rather weak due to the low thiol content 
[35]. Moreover, it is partially overlapped by the signal of the C-2 protons. For the C-TBA.2-PA 
this signal is completely overlapped by C-2 signal due to a shift to a lower resonance field. The 
thioether spectrum is distinguishable from the thiol spectrum by the shift to a lower field of the 
protons adjacent to the sulfur atom.  
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Figure 5. 3. 1H NMR spectra of (A) chitosan, (B) C-TBA.2 and (C) C-TBA.2-PA 
 
The HPLC analysis of C-TBA.2-PA was preceded by chitosanase hydrolysis of the samples. 
The purpose of this hydrolysis was to obtain covalently functionalized with phenolics 
carbohydrate oligomers to be easily analyzed by HPLC equipped with refractive index detector 
(RID) and diode array detector (DAD) at 280 nm. The soluble sugars from the enzymatically-
hydrolyzed chitosan can be separated using a specific ion exchange HPLC Aminex HPX-87H 
and detected by RID, while the absorption band of the phenolic compounds at 280 nm is easily 
identifiable with the UV detector. Using a double detection, e.g. UV at 280 nm followed by 
RID, allowed to discriminate among: i) unmodified sugars not detectable at 280 nm, ii) 
unreacted PA not detectable in RID, and iii) sugars functionalized with phenolic moieties, 
visible both in RID and at 280 nm. The chromatograms obtained using RID and DAD 280 nm 
showed common peaks detected at 16 min and 21 min (Figure 5.4A and 5.4B respectively). 
These two peaks, observed with both detectors, correspond to hydrolyzed sugars covalently 
grafted with flavonols through thiolysis reaction. The other peaks observed only at 280 nm 
corresponds to unbound phenolic moieties meanwhile the peaks detected only in RID 
correspond to unmodified soluble sugars from hydrolysis of chitosan. These evidences together 
with the 1H NMR results support the hypothesis that flavanols are covalently grafted with the C-
TBA through thioether bond. 
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Figure 5.4. RID and DAD chromatograms of hydrolysis products of functionalized C-TBA.2-PA.  
 
5.3.2. Antioxidant, antimicrobial and enzymatic inhibitory properties of 
phenolics-modified chitosan  
DPPH assay revealed an improvement of the radical scavenger activity of chitosan after 
functionalization via thiolysis (Figure 5.5). The presence of thiol and phenolic moieties 
enhanced synergistically the antioxidant activity of functionalized chitosan compared to the 
unmodified chitosan and thiolated chitosan. The antioxidant capacity of the material should 
increase with its hydrogen-donating ability. Thiols are known to possess strong hydrogen-
donating character, and as a consequence, the DPPH scavenger activity of C-TBA.2 increased 
five-fold compared to the unmodified chitosan. On the other hand, plant phenolics comprise one 
of the major groups of compounds acting as primary antioxidants or free radical scavengers [36] 
based on the ability of their phenolic moieties to donate hydrogen. The conjugation of flavan-3-
ol moieties and thiol groups results in a chitosan derivative (C-TBA.2-PA) with nearly twenty-
five fold higher antioxidant capacity compared to the unmodified chitosan, and five-fold higher 
in respect to the thiolated chitosan (sample C-TBA.2). In addition Torres et al. [7] observed that 
the new thioether bond in C4 position (Scheme 5.1) of the cysteinyl-flavan-3-ol conjugates 
enhanced their DPPH scavenger activity when compared with underivatized flavonoids. Thus, 
the functionalization of chitosan with both thiol and phenolic moieties exerts a synergistic effect 
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enhancing the antioxidant capacity of the biopolymer by an increase of the number of hydrogen-
donor groups, and the presence of thioether bond in the flavan-3-ol derivatives. 
 
Figure 5.5. DPPH radical scavenging activity of chitosan (C), thiolated chitosan (C-TBA-2), and phenolics-
functionalized chitosan (C-TBA-PA). 
 
The antimicrobial effect of unmodified chitosan was much greater for Gram positive (S. aureus) 
than for Gram negative (P. aeruginosa) bacteria. The phenolics-chitosan conjugate improved 
the antimicrobial behavior of chitosan against P. aeruginosa, while decreased its antimicrobial 
capacity against S. aureus. The incorporation of polyphenols, in addition to the thiol 
modification lowered the antimicrobial effect in the case of S. aureus, probably due to the 
reduced availability of free amino groups in the sample. In the case of P. aeruginosa an 
enhancement of antimicrobial effect was observed after thiolation and phenolics incorporation 
(Table 5.4). 
The most widely accepted mechanism for bacteria inhibition by chitosan is through the 
interaction between its cationic amino groups and negatively charged microbial cell membranes, 
resulting in the alteration of the membrane wall permeability. This mechanism has been 
reported to be common for both strains but exhibit a stronger effect on the cell membrane of S. 
aureus [37]. The decrease of antimicrobial activity against Staphylococcus aureus was due to a 
decrease of the amount of free amino groups, while the increase of the antibacterial activity 
against Pseudomonas aeruginosa, could be due to the presence of phenolic moieties [38]. 
Higher functionalization degree means lower availability of free amino groups in chitosan 
structure, reflected negatively in its antibacterial capacity against S. aureus. The tolerance of 
bacteria for phenol compounds depends on the bacteria species and the molecular structure of 
the phenolics. The present extract is rich in epigallocatechins  gallate (Table 5.1) that have been 
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reported to possess antimicrobial activity against P. aeruginosa [39] through damaging the cell 
membrane.  
 
Table 5.4. Inhibitory effect of chitosan-phenolics samples after 24 h incubation with S. aureus and P. 
aeruginosa.  
 (MIC (mg/mL) 
Sample name Staphylococcus aureus Pseudomonas aeruginosa 
C <1 >500 
C-TBA.2 8 250 
C-TBA.2-PA 8 125 
 
In this study, thiolated chitosan (C-TBA.2) showed improved inhibitory activity over 
collagenase and MPO compared to the unmodified polymer (Fig. 6). Thiolated polymers have 
been already reported to possess inhibitory effect against collagenase and MPO activity as a 
function of the degree of thiolation [40]. Nevertheless, the inhibition of collagenase and MPO in 
the presence of thiolated chitosan functionalized with PA (C-TBA.2-PA) further increased by 
22% and 32% respectively, pointing out the effectiveness of PA incorporation. Our previous 
studies showed a dose-dependent collagenase and MPO inhibition by H. virginiana extracts 
[26]. Translated to the wound environment, this combined MPO and collagenase inhibition 
would lead to the attenuation of enzymes activity and consequently allow the healing to 
progress. 
 
Figure 5.6. Effect of chitosan functionalization on major chronic wound enzyme activities A) Collagenase 
and B) MPO. All results are mean values of three replicates ± standard deviation. 
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5.5. Conclusion 
A new method for covalent grafting of plant-derived antioxidant polyphenols on high molecular 
weight substrates, e.g. chitosan using thioacidolysis reaction was developed. The generated 
products combine multiple functional groups, such as amino, thiol, imino and phenolic moieties. 
The new compounds described here result from the breakdown of oligomeric proanthocyanidins 
in the presence of thiolated chitosan. The new chitosan conjugate (C-TBA.2-PA) showed 
increased antioxidant activity and inhibitory capacity over both collagenase and MPO 
enzymatic activities in comparison with the non-functionalized chitosan (C), and thiolated 
chitosan (C-TBA.2). Furthermore, the new conjugate showed increased antimicrobial efficiency 
against the Gram negative Pseudomonas aeruginosa. Both features, strong antioxidant activity 
and an inhibitory effect on P. aeruginosa, are potentially beneficial for wound healing 
processes. Therefore thioacidolysis seems to be a promising approach to obtain biopolymeric 
matrices with enhanced functional properties for wound treatment applications. 
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6.1. Introduction 
The different chronic wound types do not share origin or cause, however they feature bacterial 
infection and high concentrations of matrix metalloproteases (MMPs), myeloperoxidase (MPO) 
and reactive oxidative species causing excessive degradation of the extracellular matrix (ECM) 
and the growth factors [1]. In healing wounds the MMPs are counteracted by their natural 
inhibitors [2], while in chronic wounds the ratio proteases/inhibitors is disturbed and most of 
these enzymes are uninhibited. The protease-antiprotease unbalance is further promoted by 
MPO-generated hypochlorous acid (HOCl), which from one sides inactivates the protease 
inhibitors and from another triggers the activity of latent MMP [3]. In addition, most chronic 
wounds are colonized with several bacterial species, e.g. Staphylococcus aureus and 
Pseudomonas aeruginosa [4]. 
Therefore, to stimulate the wound repair a dressing material should simultaneously: i) control 
the proteolytic and oxidative enzymes in the wound site, ii) provide a microorganism-free 
environment, and iii) maintain the tissue moisture while absorbing the excessive exudates. 
Biopolymers with intrinsic antimicrobial and/or healing promoting properties, such as chitosan 
and collagen/gelatin have been suggested for wound treatment, and though many of them are 
available on the market [5] only few are commercialized as chronic wound dressings. Chitosans 
of animal and fungal origin are linear and partly acetylated (1→4)-2-deoxy-β-D-glucans with 
intrinsic antimicrobial properties [6, 7]. On the other hand, gelatin (denatured collagen) besides 
ensuring the cell adhesion and growth [8], could serve as a competing substrate for several 
proteases present in the wound site thereby diverting them from digesting the ECM.  
Chitosan and collagen/gelatin dressing materials are normally produced in the form of 
hydrogels according to the widely accepted concept of moist wound healing. The dressing 
stability in chronic wound application might be compromised by the requirement for low 
frequency of changing. Thus, these hydrogels need to feature biostability and mechanical 
strength achievable by additional crosslinking [9]. To this end, various chemical cross-linkers 
have been used, however, their cytotoxicity makes them unsuitable for biomedical applications 
[10]. The search for safe, natural crosslinking agents has brought about the use of genipin due to 
its low cytotoxicity [11] as well as plant polyphenolics, such as proanthocyanidins (PA) [12] 
and hydrolysable tannins (HyT) [13] among others for stabilization of carbohydrate/protein 
systems [14]. In the case of polyphenols, stabilization of carbohydrate and protein matrices is 
thought to be due to the physical interactions between these compounds and biopolymers. Such 
natural compound-based approaches can further be upgraded by the application of highly 
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specific enzymatic tools to achieve stable, covalently cross-linked gels. Oxidative enzymes, 
such as tyrosinase, peroxidase and laccase, are able to promote inter- and intra-molecular 
coupling reactions in biopolymers and natural phenolics  [15-17]. For example, laccase (EC 
1.10.3.2) would oxidize the phenolic compounds (PC) and tyrosine residues in proteins into 
reactive quinones, which can further react with nucleophiles such as amino groups from 
chitosan and gelatin by 1,4-Michael addition or Schiff base formation. On the other hand, PA 
and HyT are known for their antioxidant capacity, antimicrobial effect, anti-inflammatory and 
wound healing promoting properties [18]. Polyphenolic extracts from Hamamelis virginiana 
(Witch-hazel) rich in PA and HyT, are widely used in the therapy of skin diseases [19-21]. 
These extracts are able to protect cells from free radicals inhibiting the proliferation of 
melanoma cells [20] and exert an inhibitory effect over deleterious chronic wounds enzymes in 
vitro [22]. The therapeutic superiority of the extracts compared to the isolated single 
constituents at equivalent doses [23] was the reason to use as cross-linkers the natural extract 
instead of the single phenolic substances. 
This study aims to generate hydrogel dressings for chronic wound application containing 
chitosan, gelatin, and natural phenolics further cross-linked by laccase to obtain bioactive and 
biostable materials with tunable physicomechanical and functional properties. Polyphenolic 
extract from Hamamelis virginiana will be oxidized by laccase in a one-step process under mild 
reaction conditions to covalently crosslink chitosan and gelatin. It is intended that the 
polyphenols play a dual role in the hydrogel: i) “passive” – being a structural element, and ii) 
“active” – modifying the chronic wound environment by attenuating the deleterious MMPs, 
MPO and ROS activities, and the bacterial infection.  
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6.2. Materials and methods 
6.2.1. Reagents 
Gelatin (G) was purchased from Fluka (France) and 90 kDa chitosan (C) from Agaricus 
bisporus was kindly supplied by KitoZyme (Belgium). Both C and G had pharmaceutical grade. 
Hamamelis virginiana (witch hazel) stems were provided by Martin Bauer GmbH (Germany).  
Trametes sp. laccase (EC 1.10.3.2, Laccase L603P, 300 U/g of solid (activity measured at 45 ºC, 
pH 4.5, 1U: µmol of oxidized ABTS/min)) was purchased from Biocatalysts (UK). Collagenase 
from Clostridium histolyticum (ChC) (1676 U/mg solid, 1 U hydrolyses 1.0 μmol of FALGPA 
per minute at pH 7.5 and 25 ºC in the presence of Ca2+) and N-(3-[2-Furyl]Acryloyl)-Leu-Gly-
Pro-Ala (FALGPA) collagenase substrate from Sigma-Aldrich (Spain) were used. 
Myeloperoxidase (MPO) from human leukocytes (1550 U/mg solid: 1 U will produce an 
increase in absorbance at 470 nm of 1.0 per minute at pH 7.0 and 25 °C, calculated from the 
initial rate of reaction using guaiacol as a substrate) comes from Planta Natural Products 
(Austria). Lysozyme from chicken egg white  (dialyzed and lyophilized powder, 100000 
units/mg solid (1 U corresponds to the amount of enzyme which decreases the absorbance at 
450 nm by 0.001 per minute at pH 7.0 and 25 °C (Micrococcus luteus, ATCC 4698, as a 
substrate)) comes from Sigma-Aldrich (Spain). All other reagents used were of the highest 
grade commercially available from Sigma-Aldrich. 
Cetrimide agar, Baird Parker agar and trypticase soy broth (TSB) were purchased from Sigma-
Aldrich. Bacterial strains Pseudomonas aeruginosa, CECT 110T and Staphylococcus aureus, 
CECT 86T were provided by the Spanish Type Culture Collection (CECT) and grown in 
cetrimide and Baird Parker agar respectively.  
 
6.2.2. Extraction and isolation of PC from Hamamelis virginiana 
The phenolic extract from H. virginiana was obtained as previously reported in chapter 3. 
 
6.2.3. Hydrogels preparation 
Gelatin solution 2 % (w/v) was prepared in 25 mM succinate buffer at pH 4.5 and 60 °C. 
Chitosan was dissolved in 1 % HCl to obtain 2 % (w/v) solution, and the pH was adjusted to 4.5 
with 1M NaOH. The solutions of chitosan and gelatin were mixed (C/G) at 2:3 ratio (w/w) at 
room temperature overnight. Thereafter, 11.25 mL of 1 % PC solution (w/v) in 25 mM 
succinate buffer pH 4.5 was added to 75 mL of the previously prepared C/G mixture 2:3 (w/w). 
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The crosslinking reaction was initiated by the addition of 1.5 mL of laccase solution (2 U/mL) 
and left to proceed for determined time periods up to 24 h at 45 °C under continuous stirring. 
The enzymatic reaction was terminated by heating at 100 ºC for 2 min and the resulting 
mixtures were cooled down to -80 °C and freeze-dried. The samples were designated according 
to the time of the enzymatic reaction. Control mixtures C/G-PC-C and C/G were prepared 
following the same procedure, but omitting the enzyme, or both PC and the enzyme (Table 6.1). 
 
Table 6.1. Coding and reaction parameters of hydrogels.  
Code Name Initial concentration of PC in reaction mixture (µg GAE/ g hydrogel)a 
Laccase incubation time 
(hours) 
C/G No PC No laccase 
C/G-PC-C 25500  No laccase 
C/G-Lacc No PC 4 
C/G-PC-2h 25500 2 
C/G-PC-4h 25500 4 
C/G-PC-6h 25500 6 
C/G-PC-8h 25500 8 
aGallic Acid Equivalents (GAE) 
 
6.2.4. Hydrogels characterization 
6.2.4.1. Rheological studies 
Rheological measurements were carried out with an ARG2 rheometer (TA Instruments, UK) 
equipped with electrical heated plates. The samples were analyzed in parallel plate geometry (25 
mm diameter) at 45 °C. The liquid samples were transferred to the preheated plate immediately 
after mixing the corresponding solutions for each test (time t = 0) and the measurements started 
at t = 60 s after thermal equilibration. The rheometer was operated in the oscillatory mode. A 
multiwave analysis program (1 Hz frequency, 3 and 5 Hz harmonics) with controlled 2 % strain 
was used to monitor the crosslinking process. The gelation time was determined using the G' 
and G" crossover criterion at 1 Hz, and as the frequency independent crossover of the tan δ 
curves at the different frequencies. To measure the mechanical properties of the resulting 
hydrogels, each experiment was repeated for defined reaction times, and the hydrogel was 
subjected to a stress sweep from 0.01 to 1000 Pa in the oscillatory mode at 1 Hz. 
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6.2.4.2. FTIR characterization of the chitosan/gelatin blends 
Infrared spectra of the blends were collected over the 3500 - 800 cm-1 range using Perkin-Elmer 
Spectrum 100 (Perkin-Elmer, Massachusetts, USA) equipped with universal ATR sampling 
accessory, performing 50 scans for each spectrum. 
6.2.4.3. Surface morphology of the hydrogels   
Scanning electron microscopy (SEM) micrographs of the hydrogels with magnification x25 
were obtained using a FESEM, Quanta 200 FEG (FEI Company, USA). 
6.2.4.4. PC release from the hydrogels 
The release of phenolics from the hydrogels was estimated according to the Folin-Ciocalteu 
method for determination of total phenol content in solution [24]  by monitoring the reaction at 
760 nm  in a microplate reader (Infinite M200, Tecan, Austria) and the results were expressed in 
gallic acid equivalents (GAE). Freeze dried C/G-PC hydrogels were incubated in PBS at pH 7.4 
and 37 °C for 60 h. At defined time intervals aliquots of the supernatant were removed, the total 
phenol content determined, and the phenolics release calculated according to equation 6.1. 
Cumulative release (%) = PCrel/PCi x 100  Equation 6.1.  
where PCi is the total amount of PC and PCrel is the amount of PC released in PBS.  
6.2.4.5. Stability of the hydrogels 
After reaching swelling equilibrium in PBS at 37 °C the hydrogels were removed from the 
medium, weighed and reintroduced to the medium. Thereafter, 1 mg/ml lysozyme was added. 
At regular time intervals, the hydrogels were removed from the medium and weighed. The 
medium was refreshed once a day. The results were compared with those obtained following the 
same procedure but omitting lysozyme. All experiments were performed in triplicate and the 
average weight loss value was calculated using equation 6.2. 
Weight loss (%) = (Ws – W Lys) / Ws x 100  Equation 6.2 
where WS is the weight of the wet hydrogel at swelling equilibrium in PBS and WLys is the 
weight of the sample after lysozyme degradation. 
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6.2.5. Assessing in vitro the bioactivity of C/G-PC-2h  
6.2.5.1. Hydrogel cleaning pre-treatment 
In order to discriminate between the bioactivity due to released PC and the bioactivity of the 
hydrogel matrix itself, hydrogel samples were submitted to an extensive cleaning process to 
remove the non-covalently bonded PC. The hydrogels were incubated in PBS, changed several 
times, until no PC release was observed spectrophotometrycally. Afterwards the hydrogels were 
washed with Milli-Q H2O to remove the salts from PBS, and then the samples were lyophilized. 
The cleaned hydrogel is refers in the text as hydrogel platform. 
6.2.5.2. Radical scavenging activity 
The radical scavenging activity of released PC and hydrogel platform  was determined 
separately measuring the decrease in absorbance of 1,1-diphenyl-2-picrylhydrazyl radical 
(DDPH) at 515 nm [25]. All experiment were carried out in triplicate and the results of the 
assay were expressed relative to Trolox in terms of TEAC (Trolox equivalent antioxidant 
capacity)  (mM Trolox eq/g hydrogel). 
6.2.5.3. MPO inhibition 
The inhibitory effect of the blends over MPO activity was measured using guaiacol as a 
substrate [26]. Hydrogel samples were incubated with 20 µL of MPO 0.325 µM (0.60 U) and 30 
µL of guaiacol (167 mM) buffered with 450 µL PBS pH 7.4 at 37 °C. After predetermined 
incubation times 200 µL of the solution were placed in a 96-well microplate and the reaction 
was started by adding 22 µL of 1 mM H2O2. The change in absorbance at 470 nm was 
monitored during 5 cycles of 15 sec (75 sec.) using microplate reader Infinite M200 (Tecan, 
Austria). All measurements were carried out in triplicate and the activity was determined by the 
rate of absorbance increase per min and expressed as a percentage of enzyme inhibition 
compared to the control (MPO reaction mixture without sample). 
6.2.5.4. Collagenase inhibition 
The collagenase activity was measured using FALGPA substrate [27]. The collagenase was 
incubated in presence of hydrogels for different time of incubation. The hydrolysis of FALGPA 
with collagenase 0.2 µg/mL in 50 mM Tricine, containing 100 mM CaCl2 and 400 mM NaCl, 
pH 7.4 was monitored spectrophotometrically at 345 nm during 5 min, immediately after 
mixing the substrate with the enzyme. All measurements were carried out in triplicate. The 
results were expressed as a percentage of enzyme inhibition compared to the control (sample 
without hydrogel).  
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To determine the kinetics of collagenase inhibition, the collagenase was treated with 0.125 
mg/ml solution of PC for 3 h at 37 °C. FALGPA solutions (0.125 mM) were used as substrates 
in the different assays. The hydrolysis of FALGPA was monitored at 345 nm, immediately after 
the addition of  PC incubated collagenase as done in the case of collagenase hydrogel inhibition. 
The kinetic parameters were calculated from Eisenthal-Cornish-Bowden plot and secondary 
plots of Kmapp/Vmaxapp vs [I] and 1/Vapp vs [I].  
6.2.5.5. Protein adsorption on the hydrogels 
Sorption studies were performed n 50 mM Tricine, 100 mM CaCl2, 400 mM NaCl, pH 7.4.  
Hydrogel platforms were incubated with 40 μg/ml collagenase. The protein content in the 
supernatants was determined at defined time intervals over 24 h by using QuantiProTM BCA 
Assay Kit (Sigma).  
6.2.5.6. Antimicrobial tests 
Pseudomonas aeruginosa and Staphylococcus aureus were grown on Cetrimide Agar and Baird 
Parker Agar respectively at 37 °C for 24 h. A microorganism suspension in TSB of each strain 
was prepared at concentration of 104 CFU/mL. Then, the hydrogel samples (25 mg) were 
incubated under constant shaking with 25 ml of bacterial suspension in 50 mL cap sterile bottles 
at 37 °C for 24 h. Inoculated medium without sample was used as positive control, whereas as 
negative control uninoculated medium was used. To determine the inhibition of bacterial 
growth, at predetermined time intervals, the microorganism suspension (10 µL) was harvested 
in the agar plate, incubated 24 h at 37 °C and the grown CFU counted afterwards. The 
measurements were repeated three times for each sample and the average value of inhibition 
was calculated following equation 6.3 
Inhibition (%) = (CFUS – CFUC) / CFUC x 100 Equation 6.3. 
where CFUs are the colonies grown in the bacterial suspension after 24 h incubation with 
hydrogel samples and CFUC are the colonies grown in the bacterial suspension after 24 h 
incubation without sample. All measurements were carried out in triplicate and the mean values 
for bacteria inhibition are reported. 
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6.3. Results and discussion 
6.3.1. Enzymatic cross-linking and functionalization of chitosan/gelatin 
hydrogels 
The laccase-catalyzed gel formation in chitosan, gelatin and PC formulation was evaluated in 
situ by means of rheological measurements. To investigate the influence of PC and laccase 
alone on the gelation, mixtures of chitosan/gelatin/laccase (C/G-Lacc) and chitosan/gelatin/PC 
(C/G-PC-C) were monitored as controls. There was a slow evolution of the storage modulus (G 
the completion of the cross-linking process.  Laccase induced oxidation of tyrosine residues into 
tyrosyl radicals that form primarily isodityrosine and dityrosine bonds or their oxidation to 
quinones [28] allows them to undergo various coupling reactions with nucleophilic groups 
present in chitosan and gelatin [29]. Nevertheless, the laccase effect was rather limited in the 
cross-linking of chitosan and gelatin due to the low tyrosine content in gelatin (about 0.5 %) 
[30]. Thus, the cross-linked network is not enough developed to create a stable hydrogel.  
Finally, the storage modulus (G’), monitored in the rheological evolution of the C/G with PC 
and laccase, increased rapidly upon addition of laccase to C/G and PC mixtures, indicating 
crosslinking between O-quinones formed by the enzymatic oxidation of PC and the nucleophilic 
groups present in the biopolymers. The gelation point indicated the formation of an incipient 
weak elastic network with a low cross-linking density. Gelation took place after 94 min for the 
C/G-PC system (Figure 6.1.A). G’ increased steadily afterwards due to further increase of the 
cross-linking density. The loss modulus (G”) also increased due to the increase in the molecular 
weight caused by the crosslinking reaction. The relative magnitude between storage and loss 
moduli is given by tan δ (tan δ =G´´/G´), being tan δ the phase angle. Since tan δ < 1, the elastic 
solid behavior of the samples was predominant over their viscous liquid behavior. The decrease 
of tan δ confirmed the progressive cross-linking of the hydrogel. G’ leveled off after 500 min 
showing completion of the cross-linking process Beyond this point, G’ decreased and tan δ 
increased corresponding to a failure of the cross-linked structure due to brittleness and excessive 
strain. The water evaporation observed might have contributed to the failure of the gel network 
and subsequent loss of hydrogel properties.  
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Figure 6.1. Rheological characterization of the laccase-assisted cross-linking reaction. C/G (2:3, % wt), 
laccase (2 U/ml) and PC (1.5 mg/ml) in succinate buffer (25 mM, pH 4.5) at 45 °C. (A) Storage modulus 
(G’), loss modulus (G’’) and tan δ evolution, (B) Oscillation stress sweep–strain curves of C/G-PC 
hydrogels after different reaction times (2, 4, 6, 8 and 24 h). 
 
Unlike the C/G-Lacc control, the mixture of C/G, PC and laccase showed higher gelation point, 
probably owing to polymerization reactions of PC [31] retarding the cross-linking . On the other 
hand the completion of the cross-linking process after 500 min of enzymatic reaction with G’ 
values higher than 105 Pa pointed out a high cross-linking density, thereby confirming that the 
laccase activation of PC was a major factor driving the biopolymer blends to gelation. 
The maximum stress and strain endured by the hydrogel before the network failure were 
determined on the basis of stress sweeps after different reaction times. The stress and strain 
increased and decreased respectively with the increase of the laccase reaction time as a 
consequence of the increased cross-link density of the chitosan, gelatin and PC network (Figure 
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6.1.B). The changes of stress and strain were more pronounced during the first 8 h, after which 
the rate of increase of the oscillatory stress was considerably slower. These results could be 
explained by reaching the maximum cross-link density after 500 min of enzymatic reaction. 
Longer treatment time (up to 24 h) did not bring about considerable increase of hydrogel stress. 
Moreover, the samples prepared in a reaction longer than 8 h were stiff and brittle, and were not 
considered for further investigations. 
 
 
Figure 6.2.  Normalized FTIR spectra of freeze-dried C/G and C/G-PC-8h samples. The inset image 
magnifies the region from 1500 cm-1 to 1200 cm-1 
 
The complexity of the used enzymatic cross-linking approach may involve a broad range of 
molecular interactions and reactions, including electrostatic attractions, hydrogen-bonding, PC 
polymerization and, above all, the covalent linkages between C/G systems and laccase-activated 
PC. Clear differences were found in the spectrum of the control sample C/G comparing to 
sample C/G-PC-8h with the highest cross-link density (Figure 6.2). Characteristic bands at 1637 
cm-1 (amide I) and 1537 cm-1 (–NH2 bending) were observed for both samples. For C/G-PC-8h 
the peak intensity of unreacted amino groups at 1537 cm-1 as well as amide I peak at 1637 cm-1 
decreased compared to the control, indicating the involvement of these groups in the cross-
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linking reaction. Additionally, a new peak at 1260 cm-1 appeared in the region of 1215 – 1270 
cm-1 attributed to C-N stretching of aryl amides formed via Michael addition, whereas the peak 
at 1239 cm-1 attributed to alkyl amines decreased. The new bands at 789 cm-1, 837 cm-1 and 875 
cm-1 could be assigned to different pattern substitution of the aromatic rings [32]. Therefore, the 
FTIR spectra confirmed that the phenolic compounds from the H. virginiana extract were 
covalently incorporated into the C/G network and the cross-linking occurred most probably and 
predominantly via Michael addition.  
 
The cross-sectional SEM micrographs (Figure 6.3) of representative freeze-dried C/G-PC 
hydrogels revealed porous structures with different pore size and shape depending on the cross-
linking density (time of enzymatic reaction). Hydrogen bonding and ionic hydrophobic 
interactions between PA and biopolymers led to a sheet-like structure of the non-cross-linked 
control sample [33, 34]. On the contrary, the enzymatically cross-linked hydrogels presented a 
porous structure with increasing pore size as a function of the extent of cross-linking, also 
observed in similar cross-linked biopolymer systems [9]. 
 
 
Figure 6.3. Scanning electron micrographs of freeze-dryed C/G-PC hydrogels. Magnification x25. A) C/G-
PC-C; B) C/G-PC-4h and C) C/G-PC-8h 
 
6.3.2. Stability of the hydrogels 
The stability of the hydrogel at use in chronic wound management is an important parameter 
due to the requirement for less frequent changing of the dressings. The  non-cross-linked control 
sample C/G-PC-C was completely disintegrated after 1 h in PBS, unlike the recently reported 5-
days stability and pepsin digestibility of ionically formed chitosan/gelatin/PC films in water 
[34]. Similar to C/G-PC-C, the other control sample C/G-Lacc was also completely solubilized 
after 1h in PBS, confirming the poor cross-linking density in such system. On the contrary, all 
enzymatically cross-linked PC-containing hydrogels retained more than 80 % of their weight 
after 60 h in PBS (Figure 6.4). Thus, the laccase-assisted cross-linking of the hydrogels with PC 
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was a prerequisite for their stability in physiological conditions. Since the main enzyme in 
wound fluids that could hydrolyze the β(1→4) glycosidic linkage in chitosan is the lysozyme 
[35], the hydrogel stability against lysozyme digestion was further evaluated.  As expected, 
comparing the stability of the hydrogels in the presence and absence of the enzyme, faster 
degradation due to the lysozyme hydrolysis of the chitosan component was observed for all 
experimental groups (Figure 6.4A-C).  
 
 
Figure 6.4. Stability of hydrogels in PBS and PBS with lysozyme (1 mg/mL) at 37 °C as a function of time. 
(A) C/G-PC-2h ; (B) C/G-PC-4h; (C) C/G-PC-6h and (E) C/G-PC-8h. At regular time intervals, the 
hydrogels were removed from the medium and weighed. The medium was refreshed once a day. The 
results are expressed as the average of the hydrogel weight loss (stability) and are mean values from 
three replicates. 
 
 
Surprisingly, the degree of hydrogel degradation by lysozyme was inversely proportional to the 
laccase incubation time. Usually, the cross-linking should stabilize the hydrogel [36].  Samples 
C/G-PC-6h and C/G/PC-8h were completely degraded by lysozyme after 48 h incubation 
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(Figure 6.4D), whereas C/G-PC-2h preserved its structural integrity even after 60 h (Figure 
6.4A). Considering that the composition of H. virginiana extract used in the present study is 
rich in monomeric and oligomeric phenolic structures [20], these unexpected results could be 
explained by the capacity of low molecular weight PC to inactivate lysozyme as recent studies 
revealed [37]. Shorter laccase application ensures a higher amount of non-covalently loaded low 
molecular weight PC, while longer incubation time results in higher cross-linking between PC 
and C/G and further polymerization of PC [38]. Consequently, the lower availability of non-
grafted, oligomeric PC in the increasingly cross-linked hydrogels would, lead to higher 
lysozyme degradability. 
 
6.3.3. PA release  
Our previous studies demonstrated the antioxidant activity and inhibitory effect on MPO and 
collagenase of H. virginiana PC, required for the initiation of the wound healing process [22]. 
Thus, besides stabilization of the hydrogel matrix, the PC from H. virginiana were expected to 
act as active agents, which controlled release would stimulate the healing process [39]. The 
cumulative release of PC from the hydrogels obtained in this study showed two phases: an 
initial burst release during the initial hydrogel swelling, followed by a sustained release (Figure 
6.5).  Shorter laccase cross-linking treatment results in higher amount of non-covalently grafted 
PC and subsequently higher PC release. The sample C/G-PC-2h, showing the highest PC release 
and stability, was selected to study the bioactivity of the hydrogels. Replicates of C/G-PC-2h 
were submitted to an extensive cleaning process to remove the non-covalently bonded PC in 
order to distinguish the effect of the permanently modified with PC hydrogel platform. The 
following experiments were conducted with both C/G-PC-2h and cleaned C/G-PC-2h hydrogel 
platform (sample further designated as “C/G-PC-2h hydrogel platform” in the text). 
Chapter 6               Enzymatic functionalization of chitosan/gelatin hydrogels   
6.3. Results and discussion 
130 
 
 
Figure 6.5. In vitro cumulative release of non-covalently loaded PA from the hydrogels. The samples were 
incubated in PBS, pH 7.4 at 37 °C for 60 h. At defined time intervals aliquots of the supernatant were 
removed and the total phenol content determined. The results are averaged from three replicates. 
 
6.3.4. In vitro assessment of the bioactivity of the hydrogels  
6.3.4.1. Radical scavenging activity 
C/G-PC-2h hydrogel platform showed considerably higher radical scavenging activity 
compared to the activity of the released PC (Table 6.2), accounting for the low liberation of PC 
(only 4 % in 24 h) from the hydrogel (Figure 6.5). As expected, the antioxidant activity of the 
released PC measured at predefined time intervals (1 – 24 h) increased gradually with time.   
At the same time the activity of the C/G-PC-2h hydrogel platform increased as well possibly 
due to swelling of the hydrogel allowing higher accessibility of DPPH to react with the 
covalently incorporated in the bulk of the hydrogel PC. PA efficiently scavenged ROS both 
upon release and acting from the biopolymer matrix. 
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Table 6.2. DPPH radical scavenging activity of released PC and C/G-PC-2h hydrogel platform. The radical 
scavenging activity was determined measuring the decrease in absorbance of DPPH radical at 515 nm. 
The results represent mean values from three replicates ± standard deviation 
 TEAC (mM Trolox/g hydrogel) 
Incubation time Released PC C/G-PC-2h hydrogel platform 
1 h 1.78 ± 0.01 54.70 ± 9.11 
2 h 2.00 ± 0.01 57.00 ± 4.42 
6 h 2.02 ± 0.00 58.32 ± 4.18 
8 h 2.05 ± 0.01 56.35 ± 9.12 
24 h 2.10 ± 0.01 59.09 ± 2.20 
 
6.3.4.2. Inhibition of chronic wound enzymes  
Chronic inflammation leads to the accumulation of MPO-generated HOCl able to oxidize most 
biological molecules. In addition HOCl triggers the MMPs activation. [10]. The stimulated 
proteolytic activity contributes to ECM degradation and chronicity of the wounds. It is therefore 
crucial to control the MPO and MMPs activities in order to provide conditions for healing and 
ECM reconstruction. The levels of HOCl can by modulated by: i) MPO substrates diverting the 
enzyme from generating HOCl, and ii) HOCl scavengers. 
In this study, both C/G-PC-2h and C/G-PC-2h hydrogel platform  inhibited the collagenase 
activity (higher inhibition with C/G-PC-2h) during the first 8 h of incubation, followed by a 
sustained inhibitory effect up to 24 h. Moreover, the profile of the collagenase inhibition curve 
in presence of C/G-PC-2h hydrogel platform  was similar to the collagenase adsorption curve 
(Figure 6.6.A and Figure 6.6.B) suggesting that enzyme protein adsorption on the hydrogels 
partially inactivates the collagenase. On the other hand, the higher inhibitory efficiency of C/G-
PC-2h sample could be related to the released PC [22]. A dose-dependent collagenase inhibition 
was reported for different plant polyphenol extracts. Interaction of the phenolic molecules with 
the enzymes was suggested to induce conformational changes or blocking of the enzyme active 
site [40].  
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Figure 6.6. Attenuation of collagenase activity in the presence of PC-cross-linked hydrogels. A) Inhibition 
of collagenase activity in the presence of PC-cross-linked hydrogels. The samples and the enzyme (0.2 
µg/mL) were incubated in 0.05 M Tricine buffer pH 7.5 (with 0.4 M NaCl and 0.01 M CaCl2, at 37 °C for 3, 
6 and 24 h. The reaction was initiated by the addition of FALGPA (300 mM) and the decrease of 
absorbance at 324 nm was monitored during 5 min to detect FALGPA hydrolysis products. B)Collagenase 
adsorption on C/G-PC-2h hydrogel platform. The samples and the enzyme were incubated in 0.05 M 
Tricine buffer pH 7.5 (with 0.4 M NaCl and 0.01M CaCl2, at 37 °C for 24 h. The protein content in the 
supernatant was measured at predetermined incubation time using QuantiProTM BCA Assay Kit. All 
results represent mean values of three replicates ± standard deviation 
 
To analyze the inhibition of collagenase by released PC, its activity was studied in presence of 
different concentrations of PC and FALGPA. The direct-linear Eisenthal-Cornish-Bowden plot 
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(Figure 6.7) describing the kinetics of collagenase inhibition by PC revealed a mixed-type 
inhibition mechanism. 
The kinetic collagense-PC dissociation constant (Kic) and collagenase-FALGPA-PC 
dissociation constant (Kiu) (Cornish-Bowden notation) were calculated by secondary plots of 
Kmapp/Vmaxapp vs [PC] and 1/Vapp vs [PC] and the Kic and Kiu values obtained were 6.1580 
mM and 0.3904 mM respectively. These data suggest that the released PC bind both to 
collagense and the collagenase–FALGPA complex probably promoting conformational changes 
in the enzyme structure and inhibiting its activity [41]. Mixed-type inhibition may be considered 
as a consequence of the presence of different phenolic compounds in Hamamelis virginiana 
extract acting by different inhibition mechanisms [40-42]. These experiments indicate that the 
proteolytic activity regulation by the developed hydrogels was due both to release of PC and 
adsorption of the enzyme protein on the biopolymer matrix. 
 
Figure 6.7. Direct-linear Eisenthal-Cornish-Bowden plots of the inhibition of collagenase at various fixed 
concentrations of PC with FALGPA as a substrate. The enzyme (0.2 µg/mL) was incubated in 0.05 M 
Tricine buffer pH 7.5 (with 0.4 M NaCl and 0.01M CaCl2, at 37 °C for 3 h) in presence of different 
collagenase concentrations. The reaction was initiated by addition of four different concentrations of 
FALGPA for each concentration of PA and the decrease of absorbance at 324 nm was monitored during 5 
min to detect FALGPA hydrolysis products. The results represent mean values of three replicates.  
 
In a next step the MPO inhibitory capacity of C/G-PA-2h and C/G-PC-2h hydrogel platform 
was measured. The C/G-PC-2h hydrogel platform did not show any MPO inhibition, while the 
C/G-PC-2h caused about 95 % enzyme inhibition within 10 min, further maintained up to 3 h 
and then followed by a decrease to 79.7 % in 24 h (Table 6.3).  
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Table 6.3. Myeloperoxidase (MPO) inhibitory activity. C/G-PC-2h was incubated with 0.60 U MPO in the 
presence of guaiacol (final concentration 10 mM) buffered with PBS pH 7.4 at 37 °C. After predetermined 
incubation times MPO activity was measured and expressed as a percentage of enzyme inhibition 
compared to the control (MPO reaction mixture without sample). The results are mean values of three 
replicates ± standard deviation. 
Sample MPO incubation time (min) MPO Inhibition activity (%) 
C/G-PC-2h 10 95.66 ± 0.58 
  30 95,93 ± 0.19 
  60 95,55 ± 0.28 
  180 94,84 ± 0.36 
  360 88.00 ± 2.13 
  1440 79.70 ± 0.61 
C/G-PC-2h hydrogel 
platform 10-1440 No inhibition 
 
The inhibition of MPO was due to the released PC acting as inhibitors and competing substrates 
for MPO in the enzyme activity assay using guaiacol [22]. If translated to the chronic wound 
environment, this combined MPO inhibition and the diversion of the enzyme from its natural 
cycle would lead to the attenuation of HOCl levels and consequently allow the healing to 
progress. 
6.3.4.3. Antibacterial studies  
The antimicrobial activity of the enzymatically-assembled hydrogels was evaluated against the 
Gram-positive Staphylococcus aureus and the Gram-negative Pseudomonas aeruginosa. The 
hydrogels inhibited the growth of both strains after 24 h incubation (Table 6.4). The inhibition 
of S. aureus growth was more pronounced than that of P. aeruginosa (respectively 85 and 45 % 
for the C/G-PC-2h, and 53 and 23 % for C/G-PC-2h hydrogel platform). The tolerance of 
bacteria for polyphenols depends on the bacteria species and molecular structure of the 
polyphenols. The extract of Hamamelis virginiana is rich in epicatechins (EC) which possess 
antimicrobial activity against S. aureus [43] and epigallocatechin gallates (EGCG) that exert 
antimicrobial activity against P. aeruginosa [44] through perturbation of the cell membrane. 
The higher antibacterial activity observed for C/G-PC-2h was probably due to the release of 
non-covalently adsorbed PC containing both EC and EGCG. On the other hand, the intrinsic 
antibacterial properties chitosan are believed to be determined by interactions between its 
cationic amino groups and the negatively charged microbial cell membranes, resulting in 
alteration of membrane wall permeability. This mechanism has been reported to be common for 
both strains, though more efficient on the cell membrane of S. aureus [45]. Therefore, the 
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antibacterial capacity of the chitosan/gelatin/PC hydrogels is a result of the combined action of 
the biopolymer platforms, covalently attached PC and released PC.  
 
Table 6.4. Inhibitory effect of hydrogels after 24 h incubation with S. aureus and P. aeruginosa. The 
hydrogels were incubated in TSB bacterial suspension of each strain (104 CFU/ml) for 24 h at 37 ºC. The 
results are mean values of three replicates ± standard deviation. 
  Inhibition of bacterial growth (%) 
  Staphylococcus aureus Pseudomonas aeruginosa 
C/G-PC-2h  84.32 ± 7.56 37.06 ± 6.34 
C/G-PC-2h hydrogel platform  65.31 ± 2.12 23.59 ± 1.03 
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6.4. Conclusions 
Laccase-assisted coupling between polyphenols of Hamamelis virginiana and primary amino 
groups in chitosan and gelatin was used as a versatile functionalization method to obtain stable 
under physiological conditions bioactive hydrogels.  The laccase-initiated oxidation of 
phenolics resulted in a biopolymer network stabilized by quinones /amino coupling reactions 
predominantly via Michael addition mechanism between the phenolic compounds and the 
polymers. The phenolic compounds loaded on the hydrogels exerted both: i) structural function 
stabilizing the hydrogel, and ii) bio-activity inhibiting deleterious wound enzymes and bacterial 
growth to stimulate the wound healing process. The physico-mechanical properties of the 
chitosan/gelatin-PC hydrogels were dependent on the duration of the enzymatic reaction.  
Hydrogels stable under physiological conditions and resistant to lysozyme degradation were 
obtained with relatively short enzymatic reaction time (2h). The inhibition of the deleterious 
chronic wound enzymes largely depended on the amount of the released phenolic compounds, 
being responsible for the inhibition of myeloperoxidase activity acting as enzyme substrates.  
On the other hand, partial inhibition of collagenase activity was due to both released phenolic 
compounds and enzyme protein adsorption onto the hydrogel platform. In addition, the 
enzymatically-assembled hydrogels inhibited the bacterial growth of Staphylococcus aureus and 
Pseudomonas aeruginosa commonly found in chronic wound.   
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7.1. Conclusions 
Abundant levels of ROS and deleterious and oxidative enzyme as MMPs and MPO are the main 
responsible to impair the normal wound healing process leading to the formation of chronic 
wounds. In addition a major complication of wound healing is the occurrence of bacterial 
infections. Ideally, because of the multifactorial nature of chronic wounds, the therapeutic 
wound healing approach should comprise wound dressings that possess the ability to directly 
and indirectly modulate the biochemical environment of the chronic wounds beyond providing 
physical protection and optimal moisture environment to encourage the healing process. 
To this end, different approaches were successfully developed during this thesis. A new method 
was developed for permanent functionalization of chitosan platform with active agents from H. 
virginiana via thiolysis reaction and a new laccase-mediated cross-linked approach to generate 
chitosan/gelatin hydrogel dressings.  
The work developed in this thesis can be divided into two main parts: The first part consist in 
the identification and study of biopolymer platforms and potential active agents (chapters 2 and 
3) and the second part consists in the development of potential wound dressings materials 
(chapter 4 and 5). The general conclusions of this research are summarized as follows: 
 
Identification and evaluation of functionalized thiolated chitosan and Hamamelis 
virginiana extracts as a chronic wound healing promoters 
The chitosan functionalized with thiol moieties was found to be efficient in the inhibition of 
collagenase, making it a suitable platform for wound dressings.  In addition the combination of -
NH2 and -SH chemistry allows to graft further other active agents onto thiolated chitosan 
platform, increasing its multi-functionality. 
Plant polyphenols from H. virginiana were found to have both a strong antioxidant activity and 
an inhibitory effect on MPO and collagenase – features potentially beneficial for the wound 
healing process. As chronic ulcer fluids contain elevated levels of ROS and neutrophil-derived 
deleterious oxidative and proteolytic enzymes, the use of thiolated chitosan as biopolymer 
platform as well as the application of extract from H. virginiana seems to be a promising 
approach for use in chronic wounds management. 
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Development of a new method for permanent for functionalization of chitosan platform 
with active agents from Hamamelis virginiana extracts 
Thiolysis reaction has been used innovatively as a synthetic approach for permanent grafting of 
phenolic antioxidants on chitosan. The resulted biopolymer platform combines multiple 
functional groups, such as amino, thiol, imino and phenolic moieties. The new chitosan 
conjugate showed increased antioxidant activity in comparison with the non-functionalized 
chitosan and thiolated chitosan. Furthermore, the new conjugate showed increased antimicrobial 
efficiency against the Gram negative Pseudomonas aeruginosa. 
The second approach focused on the use of laccase-assisted coupling between phenolic moieties 
of Hamamelis virginiana proanthocyanidins with chitosan and gelatin as a functionalization 
method to obtain stable ad bioactive hydrogels.  Hamamelis virginiana extract was oxidized by 
laccase in a one-step process under mild reaction conditions to covalently crosslink chitosan and 
gelatin. Polyphenols played a dual role in the hydrogel: i) “passive” – being a structural 
element, obtain stable and bioactive hydrogels and ii) “active” – modifying the chronic wound 
environment by attenuating the deleterious MMPs, MPO and ROS activities, and the bacterial 
infection. 
The strong antioxidant activity, inhibition of oxidative and deleterious enzymes as well as 
antimicrobial effect of the generated biopolymer matrices, are potentially beneficial for the 
wound healing process. Therefore thiolysis of proanthocyanidins and laccase-assisted cross-
linking seems to be a promising approach to obtain biopolymeric matrices with enhanced 
functional properties for wound treatment applications. 
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6.2 Future remarks 
The results  of  this  thesis  showed  that  the new materials are  promising  candidates  for  
wound  dressing  materials.  Based on the same approaches, new morphologies can be 
developed in order to adapt the dressing to wound shape and their properties can be further 
modulated depending on wound requirements.  
The materials developed, in a further step, should also be evaluated ex vivo through the use of 
skin/wound models and real wound fluids, and ultimately evaluated in vivo.  Important 
parameters such as citotoxicity and cell proliferation should be determined.   
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